Day: August 13, 2026

A Practical Framework for Using Hyperbaric Oxygen in Tissue Salvage, Reconstruction, Trauma, Infection, and Radiation-Damaged Wounds

Hyperbaric oxygen therapy, commonly abbreviated as HBOT, can support selected surgical patients when tissue viability is threatened by hypoxia, ischemia, radiation injury, severe edema, or impaired microvascular function. Its role is adjunctive. It should strengthen an appropriate operative plan rather than replace debridement, revascularization, fracture stabilization, drainage, reconstruction, or postoperative surveillance.

The Undersea and Hyperbaric Medical Society recognizes several indications that intersect directly with surgical practice. These include compromised grafts and flaps, crush injury and other acute traumatic ischemias, delayed radiation injury, chronic refractory osteomyelitis, selected advanced diabetic foot wounds, and certain severe infections. Medicare covers a related but narrower group of conditions and applies diagnosis-specific requirements. (UHMS)

Successful integration begins before the patient reaches the chamber. Surgeons and hyperbaric physicians must agree on the diagnosis, correct remediable surgical problems, identify the tissue being preserved, coordinate treatment around the operating schedule, and define how clinical response will be measured.

HBOT Is a Surgical Adjunct, Not a Rescue for Incomplete Source Control

HBOT increases arterial oxygen tension and the amount of oxygen dissolved in plasma. This can extend oxygen diffusion from functioning capillaries into hypoxic tissue and support cellular activity in areas where edema or microvascular injury limits ordinary oxygen delivery.

Potentially relevant effects include:

• Increased oxygen delivery to viable hypoxic tissue
• Reduction of selected forms of edema
• Support for fibroblast activity and collagen production
• Promotion of angiogenic signaling
• Improved oxygen-dependent leukocyte function
• Modulation of ischemia-reperfusion injury
• Support for graft, flap, bone, and soft tissue healing

These effects require at least some functioning circulation. HBOT cannot deliver an adequate oxygen dose through a completely occluded artery. It cannot remove devitalized tissue, stabilize infected hardware, drain an abscess, evacuate a hematoma, or correct a thrombosed vascular anastomosis.

The surgical team should first ask whether the patient has a correctable mechanical, vascular, or infectious problem. Hyperbaric consultation becomes most useful after those problems have been addressed or while definitive treatment is being organized without unnecessary delay.

Build HBOT Into the Operative Strategy Early

Late referral is one of the most common barriers to effective surgical use. A hyperbaric center may be contacted only after a flap has become necrotic, a traumatic wound has undergone extensive conversion, or irradiated tissue has failed several operations.

Earlier consultation does not mean every patient should begin treatment. It allows the teams to determine:

• Whether a recognized indication exists
• Whether viable tissue remains
• What operation should occur first
• Whether treatment should begin before or after surgery
• What chamber capability the patient requires
• Whether the anticipated benefit justifies transfer and treatment burden

Three referral pathways are useful.

Emergency consultation is appropriate when tissue, limb, organ, or neurologic function is being lost rapidly. Examples include acute traumatic ischemia, arterial gas embolism during surgery, and selected severe crush injuries.

Urgent consultation is appropriate for a compromised flap, failing graft, threatened replantation, progressive postoperative ischemia, or a severe infection after emergency surgical evaluation.

Planned consultation may be appropriate for chronic refractory osteomyelitis, delayed radiation injury, selected diabetic foot wounds, and complex reconstruction within a severely irradiated field.

Compromised Flaps Are a Time-Sensitive Application

A healthy flap does not require routine HBOT. The treatment becomes relevant when a flap is hypoxic or ischemic and remains potentially salvageable.

Warning findings may include:

• Increasing pallor
• Dark venous congestion
• Cool tissue
• Delayed capillary refill
• Progressive edema
• Loss or deterioration of a Doppler signal
• Epidermolysis
• Poor bleeding after pinprick
• Expanding necrosis

The operating surgeon must first evaluate for arterial thrombosis, venous obstruction, pedicle kinking, hematoma, excessive tension, compression, or technical failure. These problems may require immediate exploration or revision.

UHMS guidance states that HBOT is neither necessary nor recommended for normal, uncompromised grafts or flaps. When compromise is caused by reduced perfusion, irradiation, or hypoxia, early treatment may help maximize the amount of viable tissue and reduce the need for complete regrafting or repeat flap reconstruction. (UHMS)

The referral should communicate:

• Type and location of the flap
• Date and time of reconstruction
• Arterial and venous anatomy
• Time that compromise was first recognized
• Clinical and Doppler findings
• Operative revision already completed
• Current photographs
• Tissue or structure requiring coverage
• Planned return to the operating room

The objective should be specific. Examples include preserving coverage over exposed hardware, reducing the area requiring debridement, or avoiding another free-tissue transfer.

Skin Grafts Require Contact With a Viable Recipient Bed

Skin graft survival depends on close contact with the recipient surface, early diffusion of oxygen and nutrients, and subsequent vascular connection.

Before considering HBOT, surgeons should correct:

• Hematoma
• Seroma
• Graft displacement
• Excessive movement or shear
• Constricting dressings
• Infection
• Inadequate wound-bed preparation
• Arterial insufficiency

HBOT may support a graft when hypoxia remains after these issues have been addressed. It cannot cause a graft floating on fluid to adhere or make exposed avascular structures suitable for grafting without additional reconstruction.

Clinical reviews describe potential benefits in composite graft survival, skin graft uptake, neovascularization, fibroblast function, and ischemia-reperfusion injury. The evidence includes laboratory research, case series, reviews, and limited controlled data, so expectations should remain individualized. (PubMed)

Medicare covers preparation and preservation of compromised skin grafts, while distinguishing this use from primary management of an ordinary wound. (Centers for Medicare & Medicaid Services)

Acute Trauma Requires Parallel Surgical and Hyperbaric Planning

Crush injury, severe open fracture, vascular disruption, reperfusion, and compartment syndrome can create a cycle of edema, microvascular compression, tissue hypoxia, inflammation, and progressive necrosis.

HBOT may help interrupt this cycle by increasing oxygen delivery while reducing edema. UHMS describes acute traumatic ischemias as conditions in which tissue survival, infection control, and healing may be threatened by the combined effects of ischemia and hypoxia. (UHMS)

Treatment must not delay:

• Hemorrhage control
• Revascularization
• Fracture reduction and stabilization
• Fasciotomy
• Debridement
• Management of rhabdomyolysis
• Antibiotic treatment
• Critical-care stabilization

The international HOLLT randomized trial evaluated early HBOT after initial surgery for severe lower-limb trauma. The study reported less tissue necrosis and better selected long-term outcomes in the HBOT group, although the combined primary endpoint of necrosis or infection was not statistically significant. The findings support selective use in severe trauma rather than routine treatment of every open fracture. (PubMed)

A trauma referral should include the injury mechanism, vascular status, fracture classification, operative reports, compartment findings, debridement history, fixation, current photographs, and planned reoperations.

Compartment Syndrome Still Requires Surgical Decompression

Acute compartment syndrome is a surgical emergency. HBOT should not be used to postpone fasciotomy when clinical findings or pressure measurements support decompression.

Possible postoperative roles include supporting muscle that remains hypoxic after fasciotomy, reducing edema, and preserving marginal tissue following a severe crush injury. The surgeon must continue to assess compartment release, muscle viability, perfusion, renal risk, and the need for repeat debridement.

A wound that continues to deteriorate after HBOT requires renewed surgical evaluation. Chamber treatment should never be interpreted as evidence that another operation is unnecessary.

Replantation and Revascularization May Leave Microvascular Risk

Restoring major arterial inflow does not immediately normalize tissue oxygenation. Replanted or revascularized tissue may remain at risk because of venous congestion, edema, endothelial injury, microvascular thrombosis, and reperfusion injury.

The surgical team must first confirm that the repair remains mechanically and technically intact. Loss of inflow, venous obstruction, a constricting closure, or compressive hematoma requires direct correction.

HBOT may then be considered when macroscopic circulation is present but marginal tissue remains threatened. Monitoring should include Doppler signals, capillary refill, temperature, motor and sensory findings, edema, compartment status, and progression of necrosis.

Medicare includes acute traumatic peripheral ischemia and crush injuries involving the suturing of severed limbs among its covered hyperbaric conditions when function, limb, or life is threatened. (Centers for Medicare & Medicaid Services)

Chronic Refractory Osteomyelitis Requires an Integrated Operative Plan

HBOT is not first-line treatment for every bone infection. It may be considered for chronic refractory osteomyelitis that persists or recurs despite appropriate surgical and antimicrobial management.

Before referral, the surgical team should address:

• Sequestrated or necrotic bone
• Abscesses
• Infected or unstable hardware
• Mechanical instability
• Sinus tracts
• Vascular insufficiency
• Inadequate soft tissue coverage
• Need for bone or deep tissue cultures

UHMS notes that randomized clinical trials are lacking, but available animal studies, human case series, and nonrandomized research generally support adding HBOT to surgery and antibiotics in previously refractory disease. (UHMS)

The treatment objective may be infection remission, support before reconstruction, healing after debridement, or preservation of a limb. HBOT cannot sterilize an undebrided sequestrum or overcome unstable fixation.

The surgeon, infectious disease physician, and hyperbaric physician should agree on the sequence of debridement, antimicrobial therapy, reconstruction, and chamber treatment.

Selected Diabetic Foot Operations May Benefit From HBOT

A diabetic foot wound should not be referred simply because it is chronic, deep, or postoperative.

The patient requires comprehensive evaluation of:

• Peripheral arterial disease
• Infection and osteomyelitis
• Pressure and offloading
• Necrotic tissue
• Glucose management
• Nutrition
• Foot structure and biomechanics
• Reconstructive options

The 2023 IWGDF guideline conditionally recommends considering systemic HBOT for neuro-ischemic or ischemic diabetes-related foot ulcers when standard care has failed and appropriate treatment resources already exist. The certainty of evidence is low, reinforcing the need for selective use. (IWGDF Guidelines)

Medicare generally requires a diabetes-related lower-extremity wound classified as Wagner grade III or higher and no measurable healing after at least 30 days of standard treatment. HBOT must continue alongside vascular management, debridement, offloading, glucose optimization, infection control, and appropriate wound care. (Centers for Medicare & Medicaid Services)

Surgery should not be postponed when the patient has gangrene, deep abscess, necrotizing infection, severe ischemia, or unstable osteomyelitis. The 2023 IWGDF and IDSA infection guideline emphasizes urgent or early surgical involvement for severe and selected moderate diabetes-related foot infections. It also advises against using HBOT solely to treat infection because evidence for infection control alone is limited. (IDSA)

Radiation-Damaged Tissue Requires Organ-Specific Planning

Radiation may produce progressive small-vessel injury, fibrosis, chronic hypoxia, and reduced healing capacity months or years after treatment.

Surgeons may encounter:

• Soft tissue radionecrosis
• Osteoradionecrosis
• Chronic ulceration
• Fistula
• Wound breakdown after surgery
• Failure of grafts or flaps
• Poor tissue quality before reconstruction

HBOT is an established indication for selected delayed radiation injuries, but the evidence is not identical across every organ or operation. (UHMS)

The referral should include:

• Cancer diagnosis
• Radiation field, dose, and dates
• Current imaging
• Pathology or biopsy findings
• Previous operations
• Extent of soft tissue and bone injury
• Evidence excluding recurrent malignancy
• Planned debridement or reconstruction

A new wound or mass within an irradiated field should not automatically be labeled radionecrosis. Recurrent cancer, infection, vascular disease, and a second malignancy may need to be excluded.

Avoid Automatic HBOT for Dental Surgery in Irradiated Bone

Historical protocols frequently used HBOT around dental extraction or mandibular surgery after head and neck radiation. Current evidence supports a more selective approach.

The 2024 ISOO-MASCC-ASCO guideline concluded that routine use of HBOT for prevention or management of jaw osteoradionecrosis remains largely unjustified because supporting evidence is limited. (ASCO Publications)

Consultation may still be considered for established osteoradionecrosis, combined bone and soft tissue injury, failed prior management, or complex reconstruction in a markedly compromised field. The decision should be individualized by oral surgery, head and neck oncology, reconstructive surgery, and hyperbaric medicine.

A history of radiation alone should not trigger an automatic chamber protocol.

Necrotizing Infection Requires Cautious Integration

Necrotizing soft tissue infection and clostridial myonecrosis require immediate surgery, broad antimicrobial therapy, resuscitation, and critical care.

HBOT must never delay the initial debridement or a necessary return to the operating room. Professional guidance is not uniform. UHMS recognizes selected severe infections within its indication framework, while the IDSA skin and soft tissue infection guideline does not recommend HBOT for clostridial myonecrosis because proven benefit is lacking and transfer or treatment may delay resuscitation and debridement. (UHMS)

A responsible approach is to consider HBOT only when:

• Source control has already begun
• Broad antimicrobial therapy is active
• The patient is sufficiently stabilized
• The chamber is located within a facility capable of continuing surgical and intensive care
• Treatment will not delay another operation
• A qualified team identifies a specific adjunctive objective

The operating surgeon retains responsibility for repeated wound exploration and source control.

Plan HBOT Around the Operating Room

The chamber schedule should accommodate surgery, not compete with it.

The surgical and hyperbaric teams should agree on:

• Whether HBOT should occur before or after the operation
• The timing of dressing changes
• When the wound will be inspected
• Whether the patient needs repeated debridement
• How grafts or flaps must be positioned
• Which drains and devices can enter the chamber
• Criteria requiring immediate return to surgery
• Treatment continuation and discontinuation criteria

For a compromised reconstruction, treatment may begin after surgical revision and continue once or twice daily during the early salvage period. For chronic radiation injury or refractory osteomyelitis, treatment may occur once daily over several weeks and may be coordinated around a planned operation.

There is no single perioperative HBOT schedule appropriate for all surgical indications. Pressure, duration, frequency, air breaks, and total sessions should be prescribed according to the diagnosis, urgency, response, and patient tolerance.

Define the Endpoint Before Treatment Begins

A course should begin with a measurable clinical objective.

Possible surgical endpoints include:

• Preservation of a flap
• Increased percentage of graft uptake
• Reduction in the area requiring debridement
• Coverage of exposed bone, tendon, vessel, or hardware
• Preservation of a replanted body part
• Infection remission after osteomyelitis treatment
• Preparation of irradiated tissue for reconstruction
• Healing of a qualifying diabetic wound
• Avoidance of a more proximal amputation

The treatment plan should also define reasons to stop or revise therapy:

• Progressive necrosis
• Loss of vascular inflow
• Recurrent hematoma or venous obstruction
• Uncontrolled infection
• Need for urgent surgery
• Lack of objective improvement
• Achievement of the clinical goal
• Treatment-related risk exceeding expected benefit

Chamber attendance is not an outcome. Durable tissue survival, infection control, wound closure, functional preservation, and successful reconstruction are outcomes.

Review Dressings and Surgical Devices Before Treatment

Products that are safe in the operating room or wound clinic are not automatically safe inside a hyperbaric chamber.

The hyperbaric safety team should review:

• Negative-pressure wound systems
• External fixation
• Drains and collection devices
• Implanted electronic devices
• Infusion pumps
• Warming devices
• Topical preparations
• Petroleum-containing products
• Silver-containing dressings
• Batteries and electrical equipment
• Synthetic clothing and linens

Some devices may remain in place with modification, while others must be removed, substituted, isolated, or managed outside the chamber.

In August 2025, the FDA reminded healthcare facilities to follow chamber manufacturers’ instructions, maintain fire-prevention systems, control electrical and static-producing items, supervise patients continuously, and complete required maintenance. The communication followed reports of serious injuries and deaths associated with HBOT devices. (U.S. Food and Drug Administration)

Match the Patient to the Facility’s Capability

Not every hyperbaric center can treat every surgical patient.

A stable outpatient with delayed radiation injury may be appropriate for a wound-center program. A ventilated trauma patient receiving vasoactive medication requires a hospital-based chamber with compatible equipment, trained personnel, critical-care support, and a plan for deterioration under pressure.

Before transfer, confirm:

• A hyperbaric physician has accepted the patient
• The facility treats the specific indication
• The chamber can accommodate the patient’s size, position, and devices
• Ventilation, infusions, and monitoring can continue safely
• Surgical and critical-care services remain available
• Transfer will not delay a more urgent procedure

The presence of a chamber does not establish the ability to provide critical-care HBOT.

Screen for Hyperbaric Risks

The hyperbaric physician performs the final medical assessment, but surgeons should identify issues that may affect treatment planning.

These include:

• Known or suspected pneumothorax
• Recent thoracic trauma or surgery
• Significant pulmonary air trapping
• Mechanical ventilation
• Uncontrolled seizure activity
• Ear or sinus disease
• Hemodynamic instability
• Heart failure
• Glucose instability
• Severe claustrophobia
• Pregnancy
• Implanted medical devices

An untreated pneumothorax is a critical concern because trapped gas may expand during decompression. Trauma and postoperative patients require particular attention to chest imaging, drains, airway status, and pulmonary history.

Potential HBOT complications include middle-ear or sinus barotrauma, transient visual change, glucose disturbance, pulmonary pressure injury, and rare oxygen-induced seizure.

Document Medical Necessity Precisely

A surgical note should not request HBOT merely for “wound healing.”

Documentation should establish:

• The exact diagnosis
• Why the tissue is compromised
• The operation or injury involved
• Corrective procedures already completed
• Perfusion and viability findings
• Infection and source-control status
• The tissue or function being preserved
• The expected benefit of HBOT
• The plan for surgical reassessment
• Objective response during treatment

Medicare covers defined conditions rather than every surgical wound. Covered surgical intersections include acute traumatic peripheral ischemia, crush injury, chronic refractory osteomyelitis, delayed radiation injury, compromised skin grafts, and selected advanced diabetic wounds. Each indication carries its own clinical and documentation expectations. (Centers for Medicare & Medicaid Services)

Clinical recognition, Medicare coverage, and commercial payer authorization are separate determinations. A clinically reasonable treatment may not be covered under a specific policy, while a covered diagnosis may still fail medical-necessity review if standard care or severity criteria are not documented.

Create a Surgical HBOT Pathway

Hospitals integrating HBOT into surgical practice should establish a written pathway rather than relying on individual familiarity.

The pathway should define:

1. Which surgical conditions qualify for emergency, urgent, and planned consultation.
2. Who contacts the hyperbaric physician.
3. Which operations or corrective procedures must occur first.
4. How the patient is screened for chamber safety.
5. Which service retains primary responsibility.
6. How treatments are coordinated with the operating room.
7. Which findings trigger return to surgery.
8. How response and complications are documented.
9. When treatment should be stopped.
10. How outcomes are reviewed.

Regular case conferences can help align plastic surgery, vascular surgery, orthopedics, trauma, podiatry, infectious disease, wound care, and hyperbaric medicine.

The pathway should also make nonreferral criteria explicit. Routine postoperative swelling, an uncomplicated incision, a normally perfused flap, or an ordinary graft does not justify HBOT.

Measure Surgical Outcomes, Not Chamber Volume

A program should evaluate whether HBOT changes outcomes that matter to surgical care.

Useful measures include:

• Complete or partial flap salvage
• Graft uptake
• Repeat operations
• Area of tissue necrosis
• Level of amputation
• Limb function
• Infection remission
• Hardware preservation
• Wound dehiscence
• Time to durable closure
• Rehospitalization
• Treatment complications

Outcomes should be reported by indication and severity. Combining traumatic ischemia, radiation injury, diabetic foot wounds, and compromised flaps into one success rate provides little clinical value.

The program should also include patients who did not complete treatment. Reporting only successful completers can make results appear stronger than the actual experience of every patient who began therapy.

Surgical Judgment Remains Central

Integrating HBOT into surgical practice does not mean referring every difficult wound. It means recognizing the limited group of patients in whom increased oxygen delivery can support a well-defined operative objective.

The most appropriate candidates have:

• A recognized or defensible indication
• Viable but threatened tissue
• Corrected mechanical and vascular problems
• Adequate source control
• A realistic reconstructive or functional objective
• A facility capable of treating them safely
• Objective criteria for reassessment

The least appropriate candidates have irreversible necrosis, untreated arterial obstruction, undrained infection, unresolved mechanical failure, or a need for surgery that would be delayed by chamber treatment.

HBOT is most valuable when surgeons involve the hyperbaric team early, while continuing to own the operation, source control, reconstruction, and postoperative surveillance. The chamber can improve the biologic environment in selected patients, but the surgical plan determines whether that opportunity becomes durable tissue salvage.

A Hospital Blueprint for Coordinated Diagnosis, Limb Preservation, Advanced Treatment, Hyperbaric Medicine, and Measurable Outcomes

A multidisciplinary wound care program should be built around the causes of wound failure, not around a single treatment modality. Chronic and complex wounds commonly involve several interacting problems, including impaired perfusion, infection, pressure, neuropathy, edema, metabolic disease, radiation injury, malnutrition, and inadequate access to ongoing care.

No individual clinician can address every component efficiently. A wound physician may recognize tissue necrosis but require a vascular specialist to restore blood flow, a surgeon to remove infected tissue, a podiatrist to correct pressure, an infectious disease physician to guide antimicrobial therapy, and a rehabilitation professional to help the patient regain mobility.

Multidisciplinary care is particularly important in diabetes-related foot disease. An American Heart Association scientific statement describes diabetic foot ulcers as a major source of morbidity and lower-extremity amputation, while noting that care is often episodic and fragmented because patients have complex cardiovascular and metabolic comorbidities. (PubMed)

Building an effective program therefore requires more than hiring a wound specialist or purchasing a hyperbaric chamber. It requires a defined clinical scope, reliable referral pathways, shared decision-making, standardized documentation, rapid access to specialty services, and a quality system capable of measuring whether patients are actually healing.

Define the Program’s Clinical Scope

The first planning decision is which patients the program will treat.

A general outpatient wound center may manage:

• Diabetes-related foot ulcers
• Venous leg ulcers
• Arterial ulcers
• Pressure injuries
• Surgical wounds
• Traumatic wounds
• Radiation-associated wounds
• Ostomy and peristomal complications
• Compromised grafts and flaps

A hospital-based advanced wound program may also support:

• Limb-threatening infection
• Chronic refractory osteomyelitis
• Complex postoperative wounds
• Necrotizing soft tissue infections
• Acute traumatic ischemia
• Inpatient pressure injury prevention
• Reconstructive surgery
• Hyperbaric oxygen therapy

The program should distinguish between services it provides directly and services it coordinates through other departments.

For example, a wound clinic may perform vascular screening but refer patients to vascular surgery for angiography and revascularization. It may evaluate suspected osteomyelitis but coordinate bone biopsy and debridement with podiatric, orthopedic, or general surgery.

This scope should be realistic. A program should not advertise limb salvage if it lacks rapid access to vascular intervention, surgical source control, infectious disease consultation, and effective offloading.

Establish Medical and Operational Governance

The program needs clear clinical ownership.

A medical director should oversee:

• Clinical eligibility
• Evidence-based protocols
• Physician competency
• Treatment escalation
• Quality review
• Adverse events
• Utilization
• Coordination with hospital leadership

The medical director may come from wound care, surgery, vascular medicine, emergency medicine, plastic surgery, podiatry, internal medicine, or another relevant discipline. The essential requirement is sufficient wound-care expertise, organizational authority, and time to govern the program.

Operational leadership is also necessary. A program manager or clinical coordinator may oversee staffing, scheduling, supply management, prior authorization, documentation audits, referral development, and performance reporting.

The governance structure should define who is responsible for:

• The underlying disease
• The wound-care plan
• Operative decisions
• Vascular decisions
• Antimicrobial management
• HBOT prescriptions
• Inpatient consultation
• Emergency escalation
• Follow-up after wound closure

Without these distinctions, patients can receive overlapping recommendations while no clinician retains responsibility for the complete plan.

Build the Core Multidisciplinary Team

The exact team depends on the program’s patient population. A hospital limb-preservation program commonly needs access to:

• Wound-care physicians
• Wound, ostomy, and continence nurses
• Podiatrists
• Vascular medicine and vascular surgery
• Infectious disease
• General, orthopedic, plastic, or trauma surgery
• Endocrinology or diabetes management
• Nutrition
• Physical and occupational therapy
• Orthotics and prosthetics
• Case management
• Social work
• Hyperbaric medicine when available

The core team does not need to occupy one clinic simultaneously every day. It does need a reliable system for communication, urgent review, and coordinated decision-making.

A systematic review of multidisciplinary diabetic foot teams found that 94 percent of the included studies reported reductions in major amputation after team implementation. Team structures varied, but successful programs repeatedly addressed vascular disease, infection, wound management, glycemic control, and surgical needs. (PubMed Central (PMC))

The wound nurse is often the operational center of this model. Certified wound, ostomy, continence, and foot-care credentials validate specialized nursing knowledge and provide a framework for staff development. (WOCNCB)

Create a Rapid Limb-Salvage Pathway

Routine appointment scheduling is inadequate for a patient with gangrene, rapidly progressive infection, exposed hardware, acute ischemia, or a failing reconstruction.

The program should define findings that trigger same-day or emergency evaluation, such as:

• New gangrene
• Rapidly spreading erythema
• Crepitus or suspected necrotizing infection
• Deep abscess
• Systemic toxicity
• Sudden loss of pulses
• Acute rest pain or limb pallor
• Compartment syndrome
• A threatened graft or flap
• A wound with exposed vessel or unstable hardware

The 2024 multisociety guideline for lower-extremity peripheral artery disease emphasizes multidisciplinary care for chronic limb-threatening ischemia and the need to address amputation risk, health disparities, and care coordination. (professional.heart.org)

A practical pathway should specify:

1. Who accepts the initial call.
2. How quickly the patient is assessed.
3. When vascular imaging is obtained.
4. Which findings require hospital admission.
5. Who performs urgent drainage or debridement.
6. How the patient reaches the operating room or interventional suite.
7. When HBOT or another adjunct may be considered.

The goal is to eliminate delays created by sequential referrals. A patient should not wait several weeks for separate appointments while ischemia or infection progresses.

Standardize the Initial Wound Assessment

Every patient should receive a structured evaluation that identifies the wound type and the factors preventing healing.

The assessment should include:

• Wound location, duration, and cause
• Length, width, depth, and undermining
• Tissue type and exposed structures
• Drainage and odor
• Periwound skin condition
• Pain
• Edema
• Infection findings
• Peripheral pulses and perfusion
• Neurologic function
• Pressure and footwear
• Mobility
• Nutritional and metabolic factors
• Previous treatment and response

Photographs should be obtained with patient consent using a standardized technique. Consistent distance, lighting, orientation, and a measurement reference improve comparison over time.

The program should choose validated classification systems appropriate to each wound category. Examples may include Wagner or University of Texas classification for diabetes-related foot wounds, standardized pressure-injury staging, and structured infection and ischemia assessments.

The purpose of classification is not merely coding. It should help predict risk, trigger referrals, and determine the treatment pathway.

Make Vascular Assessment a Required Step

A chronic lower-extremity wound cannot be managed effectively without determining whether the tissue has enough blood flow to heal.

The vascular evaluation may include:

• Pulse examination
• Handheld Doppler signals
• Ankle-brachial index
• Toe pressures
• Pulse-volume recordings
• Transcutaneous oxygen measurement
• Duplex ultrasonography
• CT or conventional angiography

Diabetes, kidney disease, and arterial calcification can make some ankle-pressure measurements unreliable. The program needs a defined pathway for obtaining more informative testing when bedside findings and the initial study do not agree.

A vascular abnormality should lead to timely review by the appropriate specialist. Wound products and biologic therapies should not be used as substitutes for restoring correctable blood flow.

For diabetes-related wounds considered for HBOT, Medicare identifies vascular assessment and correction of vascular problems when possible as elements of required standard wound care. (Centers for Medicare & Medicaid Services)

Integrate Infection and Surgical Source Control

Wound cultures, antibiotics, and dressings cannot compensate for undrained infection or retained necrotic tissue.

The program should establish pathways for:

• Deep tissue or bone sampling
• Imaging for abscess and osteomyelitis
• Urgent incision and drainage
• Bedside or operative debridement
• Bone resection
• Hardware management
• Antimicrobial stewardship
• Reconstructive coverage

Superficial swab results may not reflect the organisms causing deep infection. The team should define when tissue or bone specimens are needed and how samples are obtained without unnecessary contamination.

Clinical decisions should also distinguish colonization from infection. Antibiotics should be used for clinically infected wounds, not simply because bacteria are present in an open wound.

The infectious disease, surgical, and wound teams should agree on the source-control plan, expected antimicrobial duration, and criteria for repeat imaging or surgery.

Treat Pressure as a Clinical Cause

Mechanical pressure is a primary cause of many diabetic foot ulcers and pressure injuries. It should be treated with the same seriousness as infection or ischemia.

The program needs access to:

• Total-contact casting
• Removable cast walkers
• Custom footwear and orthoses
• Heel offloading
• Support surfaces
• Repositioning plans
• Wheelchair assessment
• Gait and mobility evaluation

Patients should not be described as noncompliant without first examining why the prescribed device is not being used. Common barriers include instability, inability to drive, work requirements, poor fit, limited strength, home hazards, and lack of insurance coverage.

Pressure-injury treatment and prevention also require coordination beyond the outpatient clinic. The Wound Healing Society’s 2023 guideline addresses repositioning, support surfaces, debridement, nutrition, surgery, and palliative goals as interdependent components of care. (PubMed Central (PMC))

Connect Inpatient Prevention With Outpatient Treatment

A hospital wound program should not function only as an outpatient treatment center. It should also help prevent hospital-acquired pressure injuries and manage complex inpatient wounds.

An inpatient prevention pathway may include:

• Risk assessment on admission
• Comprehensive skin assessment
• Repositioning protocols
• Moisture and incontinence management
• Support-surface selection
• Device-related pressure checks
• Nutrition screening
• Early wound-team consultation
• Standardized event review

The Agency for Healthcare Research and Quality recommends an interdisciplinary approach that includes organizational readiness, an implementation team, standardized risk assessment, care bundles, measurement, and plans for sustaining improvement. (AHRQ)

Outpatient and inpatient teams should share terminology, staging standards, photography policies, and escalation criteria. Otherwise, patients may move between settings with inconsistent diagnoses and treatment plans.

Use Advanced Therapies Only After Foundational Care

An effective program may offer or coordinate:

• Negative-pressure wound therapy
• Cellular or tissue-based products
• Skin substitutes
• Growth-factor therapies
• Electrical or ultrasound modalities
• Compression systems
• Hyperbaric oxygen therapy
• Reconstructive surgery

These therapies should enter the pathway only after the wound has been diagnosed correctly and major barriers have been addressed.

Before an advanced treatment begins, the record should explain:

• Why the wound is not healing
• Which foundational treatments have been completed
• What clinical outcome is expected
• How response will be measured
• When the treatment will be stopped

Advanced technology should not become the program’s identity. The strongest program is defined by diagnostic accuracy and coordinated treatment, not by the number of products it uses.

Position HBOT as an Adjunctive Service

HBOT can strengthen a multidisciplinary program when it is used for appropriate indications and integrated with standard care.

Potential wound-related applications include:

• Selected advanced diabetes-related foot ulcers
• Chronic refractory osteomyelitis
• Delayed radiation tissue injury
• Compromised grafts and flaps
• Acute traumatic ischemia
• Selected severe infections

For Medicare coverage of diabetes-related lower-extremity wounds, the patient must have diabetes, a wound related to diabetes, Wagner grade III or higher disease, and failure to demonstrate measurable healing after at least 30 days of standard therapy. HBOT must remain adjunctive to vascular management, glucose optimization, nutrition, debridement, moist wound care, offloading, and infection treatment. (Centers for Medicare & Medicaid Services)

The hyperbaric physician should participate in multidisciplinary planning rather than receive isolated referrals after the wound has failed for months.

The program should also define:

• Referral criteria
• Contraindication screening
• Treatment protocols
• Physician supervision
• Continued-treatment criteria
• Chamber safety
• Fire prevention
• Documentation requirements
• Adverse-event review

Chamber utilization should never determine whether a patient receives or continues HBOT.

Design a Weekly Multidisciplinary Conference

A recurring case conference can convert a collection of specialists into a functioning team.

Appropriate cases include:

• Wounds failing to progress
• New limb-threatening ischemia
• Recurrent infection
• Suspected osteomyelitis
• Planned reconstruction
• Possible HBOT candidates
• Patients facing major amputation
• Patients with repeated admissions
• Cases with unclear ownership

The conference should produce decisions, not merely discussion.

Each reviewed case should end with:

• A defined wound diagnosis
• The current treatment objective
• Outstanding diagnostic needs
• Assigned clinical responsibilities
• A time frame for reassessment
• Criteria for escalation

The program may also use brief daily huddles for urgent concerns and reserve the weekly conference for complex treatment planning.

Add Patient Navigation and Access Support

A technically appropriate plan can still fail when the patient cannot reach appointments, obtain dressings, use an offloading device, or follow multiple specialty schedules.

A nurse navigator, case manager, or coordinator can help with:

• Referral scheduling
• Transportation
• Prior authorization
• Home health
• Supply access
• Medication coordination
• Patient education
• Communication among specialists
• Follow-up after hospitalization

The program should screen for practical barriers at the beginning of care rather than discovering them after repeated missed appointments.

Patient education should explain:

• The wound’s cause
• Warning signs requiring urgent care
• Dressing and skin-care instructions
• Offloading or compression requirements
• Glucose and nutrition goals
• Smoking and nicotine risks
• The expected treatment timeline

Patients are more likely to follow a demanding plan when they understand why each part matters.

Standardize Documentation and Clinical Pathways

Templates should improve clinical reasoning rather than produce repetitive text.

A wound note should document:

• Diagnosis and wound cause
• Measurements
• Tissue findings
• Perfusion
• Infection status
• Pressure or edema management
• Procedures performed
• Response since the previous visit
• Current treatment objective
• Next escalation point

Diagnosis-specific pathways can reduce variation. A diabetic foot ulcer pathway should not be identical to a venous leg ulcer or radiation wound pathway.

Standing protocols may help the team obtain vascular studies, laboratory tests, imaging, support surfaces, or urgent consultation promptly. These protocols must remain within professional scope and hospital policy.

The Joint Commission’s disease-specific certification framework emphasizes a formal program structure, evidence-based care delivery, multidisciplinary communication, and an organized method of performance measurement. Wound care is included among the areas eligible for disease-specific certification. (Joint Commission)

Measure Outcomes by Wound Type

A program should not rely on total visits, procedures, or chamber treatments as measures of success.

Clinical metrics may include:

• Time to first specialist evaluation
• Time to vascular assessment
• Time to operative source control
• Wound-area reduction
• Complete and sustained closure
• Major and minor amputation
• Infection-related hospitalization
• Graft or flap salvage
• Recurrence after closure
• Pressure injuries acquired in the hospital
• Patient-reported pain and function
• Treatment completion

Operational and financial measures may include:

• Referral-to-appointment interval
• Authorization turnaround
• Cancellation rate
• Treatment denials
• Supply expense
• Staffing productivity
• Avoidable hospital utilization
• Contribution margin by service line

Results should be stratified by wound diagnosis and severity. Combining a superficial venous ulcer with an ischemic diabetic foot wound and a radiation-associated ulcer creates an outcome rate that has little clinical meaning.

Amputation should also be reported by level. A minor procedure that removes infected tissue while preserving a functional foot is different from a below-knee or above-knee amputation.

Build Compliance Into the Program From the Start

Wound care involves significant documentation and reimbursement complexity. Compliance concerns may arise around:

• Medical necessity
• Debridement coding
• Product utilization
• Repeated procedures
• HBOT eligibility
• Physician supervision
• Place-of-service rules
• Provider-based billing
• Prior authorization

The program should use prospective documentation review and regular audits rather than waiting for payer denials or external investigation.

Clinical and financial incentives must remain separate. A clinician should be able to stop an advanced treatment when the wound is not responding, even if additional visits have been authorized.

The program should also maintain clear policies for conflicts of interest involving wound products, device vendors, management companies, and referral relationships.

Plan the Program in Phases

A phased launch reduces operational risk.

Phase one should establish governance, staffing, referral criteria, documentation, vascular access, surgical escalation, and core wound services.

Phase two may add advanced diagnostics, specialized offloading, reconstructive pathways, inpatient consultation, and more formal limb-preservation conferences.

Phase three may add HBOT, research, registry participation, regional referral agreements, or critical-care capabilities when the hospital has sufficient clinical volume and safety infrastructure.

Each phase should have defined readiness criteria. Purchasing equipment before building referral and care pathways can create pressure to generate volume before the clinical system is mature.

Build the Program Around the Patient’s Whole Pathway

A multidisciplinary wound care program succeeds when it shortens the distance between recognizing a problem and delivering the correct intervention.

The patient should not have to coordinate vascular testing, infectious disease care, debridement, offloading, nutrition, and HBOT independently. The program should create one coherent pathway that identifies the cause of the wound, assigns responsibility, and escalates care when healing does not occur.

The strongest programs share several characteristics:

• Clear medical leadership
• Rapid access for limb-threatening conditions
• Integrated vascular and surgical care
• Specialized wound nursing
• Standardized assessment
• Selective use of advanced therapies
• Patient navigation
• Diagnosis-specific outcome measurement
• Continuous quality review

A chamber, wound product, or specialty clinic may become part of that system. None of them can replace it.

Building a multidisciplinary wound care program is ultimately an exercise in clinical coordination. Its value is measured not by the number of treatments delivered, but by durable healing, preserved limbs, reduced complications, and patients returning safely to their daily lives.

What Clinical Trials, Guidelines, and Real-World Outcomes Actually Show About Hyperbaric Wound Healing

Patients and referring clinicians often ask for the success rate of hyperbaric oxygen therapy, commonly abbreviated as HBOT, in chronic wounds. The most accurate answer is that no single percentage applies across all wounds or patients.

A chronic wound may result from diabetes, ischemia, venous hypertension, pressure, infection, radiation damage, surgery, trauma, or several of these factors at once. Each wound type has a different pathophysiology, treatment pathway, and definition of success.

Even within diabetic foot ulcer research, reported results vary substantially. One well-designed trial found complete healing at one year in 52 percent of HBOT-treated patients compared with 29 percent of patients receiving sham treatment. Another sham-controlled trial found healing at 12 weeks in 20 percent of HBOT patients and 22 percent of controls. These results cannot be reconciled into a universal success rate without accounting for differences in patient selection, wound severity, ischemia, treatment completion, follow-up, and standard wound care. (PubMed)

HBOT should therefore be discussed in terms of the probability of achieving a defined outcome in a carefully selected patient, not as a treatment with one advertised cure rate.

What Counts as HBOT Success?

Success can mean several different things in chronic wound care:

• Complete wound closure
• Reduction in wound area or depth
• Development of healthy granulation tissue
• Control of refractory infection
• Preservation of a graft or flap
• Avoidance of major amputation
• Reduction in the required level of amputation
• Successful preparation for reconstructive surgery
• Durable healing without early recurrence

These outcomes are not interchangeable.

A wound that becomes smaller but remains open is not completely healed. A diabetic foot wound that closes temporarily and reopens several weeks later has not achieved sustained healing. A minor toe amputation that removes infection and preserves a functional foot may represent successful limb salvage, even though an amputation occurred.

For chronic osteomyelitis, success is generally measured through remission of infection rather than closure of a surface wound. For radiation injury, meaningful improvement may include reduced bleeding, healing of an ulcer, improved tissue quality, or successful reconstruction.

Any reported success percentage should therefore identify the outcome measured, the follow-up period, and the population treated.

Diabetic Foot Ulcers Have the Most Studied Wound Outcomes

The largest chronic wound evidence base concerns diabetes-related foot ulcers. HBOT is not intended for every diabetic ulcer. The patients studied and covered for treatment generally have advanced wounds that have failed comprehensive standard care.

The 2023 International Working Group on the Diabetic Foot, or IWGDF, conditionally recommends considering HBOT for neuro-ischemic or ischemic diabetes-related foot ulcers when standard care alone has failed and the treatment resources are available. The recommendation is rated as low certainty because the trials have produced conflicting findings and many have a high risk of bias.

The guideline found that the better-quality evidence suggested a possible improvement in complete wound healing and reduction in ulcer area. It did not find good evidence that HBOT reliably prevents amputation across the studied population. Differences in ischemia, wound definitions, treatment protocols, and follow-up periods made comparison difficult.

This is a more clinically responsible interpretation than claiming that HBOT heals a fixed percentage of diabetic wounds.

The HODFU Trial Reported Higher One-Year Healing

The HODFU study remains one of the most frequently cited HBOT wound trials. It was randomized, double-blinded, and placebo controlled, involving selected patients with chronic diabetes-related foot ulcers.

At one year, complete healing occurred in:

• 25 of 48 patients assigned to HBOT, or 52 percent
• 12 of 42 patients assigned to sham treatment, or 29 percent

The difference was statistically significant. Among patients who completed at least 36 of the planned 40 sessions, reported healing was approximately 61 percent with HBOT and 27 percent with placebo. (PubMed)

These figures show that HBOT improved the probability of healing in that specific trial. They do not mean that every patient beginning treatment has a 52 or 61 percent chance of healing.

The participants were selected for a controlled study, received structured wound care, and were followed for one year. Results may differ in patients with uncontrolled infection, uncorrected arterial disease, inadequate offloading, severe frailty, or an inability to complete the treatment course.

Other Randomized Trials Found Little or No Added Benefit

The Fedorko trial also used a randomized, double-blind, sham-controlled design. At 12 weeks, 10 patients in the HBOT group, or 20 percent, had healed compared with 12 patients in the sham group, or 22 percent. The study did not find that HBOT reduced the number of patients meeting criteria for amputation. (PubMed)

The DAMO2CLES multicenter trial studied patients with diabetes and ischemic lower-extremity ulcers. It did not demonstrate significant improvement in complete healing or limb salvage across the overall population assigned to adjunctive HBOT. Treatment completion was also a challenge, which reflects an important limitation in real clinical practice. (PubMed)

These negative trials do not prove that HBOT is ineffective for every chronic diabetic wound. They demonstrate that results depend heavily on which patients are treated, whether they complete treatment, and whether the wound’s principal barriers are responsive to oxygen therapy.

Meta-Analyses Often Report Stronger Pooled Effects

Meta-analyses combine results from multiple trials to estimate an overall treatment effect. Several recent reviews have reported improved healing with adjunctive HBOT.

A 2024 meta-analysis of seven randomized trials reported that complete healing was more frequent with HBOT, with a pooled relative risk of 3.59. The confidence interval was wide, indicating uncertainty about the exact size of the effect. (PubMed)

Another 2024 systematic review organized by Wagner grade reported an overall relative risk for ulcer healing of 2.39. The analysis also had substantial statistical heterogeneity, meaning the included study results differed considerably from one another. (PubMed Central (PMC))

Relative risk should not be confused with an absolute success rate. If 10 percent of a comparison group heals, doubling the healing probability would produce a 20 percent treatment-group rate. If 30 percent of the comparison group heals, the same relative effect would produce a much higher absolute rate.

Pooled estimates are also only as reliable as the studies included. Small samples, inconsistent wound classifications, variable standard care, and differences in treatment dose can produce a result that does not accurately predict outcomes in one hospital or one patient.

Success Is More Likely in Properly Selected Wounds

HBOT is most biologically plausible when the wound contains viable but hypoxic tissue and enough circulation remains to deliver oxygenated plasma.

Features that may support a favorable response include:

• A recognized hyperbaric indication
• A neuro-ischemic or ischemic diabetic foot ulcer
• Wagner grade III or higher disease
• Failure to heal despite appropriate standard care
• Corrected or maximally treated arterial disease
• Effective pressure offloading
• Adequate debridement and infection control
• A realistic reconstructive or limb-salvage objective
• Ability to complete the planned treatment course

HBOT is less likely to succeed when the principal barrier remains untreated. Examples include an occluded artery requiring revascularization, an undrained abscess, necrotic bone requiring removal, continued weight bearing on a plantar ulcer, or a wound bed that cannot support reconstruction.

Oxygen can strengthen healing biology. It cannot compensate indefinitely for absent blood flow, repeated trauma, uncontrolled infection, or irreversible necrosis.

Medicare Criteria Reflect Selective Use

Medicare coverage for diabetes-related lower-extremity wounds requires all of the following:

1. Type 1 or type 2 diabetes
2. A lower-extremity wound caused by diabetes
3. Wagner grade III or higher
4. Failure of an adequate course of standard wound therapy

HBOT is covered as an adjunct only after the wound has shown no measurable healing for at least 30 days despite appropriate care. Continued treatment is not covered when measurable improvement is not demonstrated within a subsequent 30-day treatment period. (Noridian Medicare)

These rules are coverage requirements rather than a complete clinical guideline, but they reinforce two essential principles. HBOT should not be the first treatment applied to an uncomplicated wound, and the course should not continue without objective evidence of benefit.

HBOT Is Not Established for Every Chronic Wound Type

The phrase chronic wound includes several conditions for which HBOT evidence is limited or absent.

For venous leg ulcers, the primary treatment is compression after appropriate arterial evaluation. HBOT research has not established a reliable complete-healing advantage for routine venous ulcer treatment.

Pressure injuries require pressure redistribution, repositioning, moisture control, nutrition, debridement, and management of contributing illness. There is insufficient controlled evidence to calculate a meaningful HBOT success rate for pressure ulcers.

Evidence is also inadequate for routine HBOT treatment of chronic arterial ulcers when arterial inflow has not been restored. A completely ischemic wound requires vascular evaluation, not an attempt to force oxygen through an absent circulation.

The major Cochrane review of HBOT for chronic wounds found that most randomized evidence involved diabetic foot ulcers. It found insufficient evidence to support routine treatment of venous, arterial, or pressure ulcers. (Cochrane)

A center should not apply diabetic foot ulcer outcome percentages to every wound referred for treatment.

Chronic Refractory Osteomyelitis Uses a Different Success Measure

Chronic refractory osteomyelitis is a recognized hyperbaric indication when infection persists or recurs despite appropriate surgery and antimicrobial treatment.

Published clinical reports have described remission rates of approximately 81 to 85 percent at two to three years. These figures are derived primarily from older observational series rather than modern randomized trials, so they should not be presented with the same certainty as a large controlled study. (AAFP)

A later systematic review found supportive results across published reports, but the evidence remained limited by nonrandomized designs and differences in surgical care, infection site, pathogens, and outcome definitions. (PubMed)

Success in refractory osteomyelitis requires more than chamber attendance. It generally depends on:

• Removal of infected or necrotic bone when feasible
• Deep cultures
• Appropriate antimicrobial therapy
• Stable fixation
• Management of infected hardware
• Adequate soft-tissue coverage
• Correction of vascular insufficiency

Current clinical guidance describes courses of approximately 20 to 40 sessions when the patient is improving. Failure to show an early clinical response should prompt reassessment of source control and the overall treatment plan rather than indefinite continuation of the same regimen. (PubMed)

Radiation Wounds Also Require Diagnosis-Specific Outcomes

Delayed radiation injury may cause chronic ulcers, exposed bone, fibrosis, bleeding, or failure of surgical tissue within a previous treatment field.

Success may involve:

• Closure of a radiation-associated ulcer
• Reduced tissue bleeding
• Improved wound-bed quality
• Healing after debridement
• Successful graft or flap reconstruction
• Remission of osteoradionecrosis symptoms

These patients should not be grouped with diabetic foot ulcer trials. Radiation injury has a different mechanism, treatment course, and outcome profile.

The tissue may require 30 to 40 or more HBOT sessions, sometimes coordinated around surgery. Complete recovery is less likely when radiation injury has caused extensive structural destruction, a fistula, pathologic fracture, or severe loss of organ function.

A reported improvement rate in radiation cystitis, for example, cannot be used as the expected closure rate for a chest wall ulcer or mandibular osteoradionecrosis.

Treatment Completion Influences Outcomes

Chronic wound protocols commonly require treatment five days per week over several weeks. This creates a substantial burden for patients who may already have limited mobility, transportation barriers, employment obligations, or multiple medical appointments.

Treatment interruptions may occur because of:

• Ear or sinus pressure difficulty
• Hospitalization
• Surgery
• Glucose instability
• Transportation problems
• Claustrophobia
• Acute illness
• Financial or caregiving demands

The HODFU results were stronger among patients who completed at least 36 sessions than in the full intention-to-treat population. This suggests that treatment completion may influence outcomes, although patients who complete therapy may also be healthier or more adherent in other aspects of wound care. (Wiley Online Library)

A success estimate should therefore specify whether it applies to all patients who started treatment or only to those who completed a minimum number of sessions.

Standard Wound Care Determines Much of the Outcome

HBOT does not operate independently of the rest of the treatment plan.

For a diabetic foot wound, standard care may include:

• Vascular testing and revascularization
• Surgical debridement
• Infection and osteomyelitis treatment
• Pressure offloading
• Glucose management
• Nutritional support
• Appropriate dressings
• Reconstruction when necessary

The IWGDF defines high-quality standard care as including debridement, offloading, revascularization, and infection treatment where appropriate. HBOT was evaluated as an adjunct to these interventions, not as a replacement for them. (IWGDF Guidelines)

A hyperbaric program reporting high closure rates may have excellent vascular, podiatric, surgical, infectious disease, and offloading services. The result should not automatically be attributed to the chamber alone.

Conversely, a low healing rate may reflect late referral, severe disease, limited access to revascularization, or poor treatment completion rather than a failure of oxygen physiology.

Early Wound Improvement Is More Useful Than a Marketing Percentage

The most valuable success estimate is often the patient’s own trajectory after treatment begins.

The care team should monitor:

• Wound area
• Wound depth
• Tissue quality
• Granulation
• Drainage
• Necrosis
• Infection findings
• Exposed bone or tendon
• Perfusion
• Offloading adherence
• Need for further surgery

A wound that demonstrates progressive granulation, reduced depth, and measurable area reduction may justify continued therapy. A wound that remains unchanged or deteriorates requires reassessment.

Potential explanations for nonresponse include:

• Recurrent or persistent ischemia
• Undiagnosed osteomyelitis
• Inadequate debridement
• Continued pressure
• Uncontrolled edema
• Malnutrition
• Tobacco or nicotine exposure
• Incorrect diagnosis
• Irreversible tissue loss

Continuing HBOT without addressing these factors is unlikely to convert a failing treatment plan into a successful one.

Complete Closure Is Not the Only Meaningful Benefit

Some advanced wounds do not close during the chamber course but still improve enough to permit a successful operation, graft, flap, or delayed closure.

Clinically meaningful intermediate outcomes may include:

• Development of a vascular granulation bed
• Coverage of exposed structures
• Reduced necrotic tissue
• Control of chronic drainage
• Reduced wound dimensions
• Transition to a simpler reconstruction
• Preservation of a functional portion of the foot
• Avoidance of a major amputation

These outcomes should be documented honestly. A wound should not be counted as healed when it merely becomes smaller, but partial progress can still have substantial value.

The final assessment should consider whether the improvement was durable and whether the patient’s function, treatment burden, and quality of life improved.

How Clinicians Should Discuss Expected Results

A balanced discussion might explain that:

• HBOT improves healing in some selected advanced wounds.
• Clinical trials report substantially different results.
• One strong diabetic foot ulcer trial reported 52 percent healing at one year compared with 29 percent after sham treatment.
• Other well-designed trials did not find an added healing benefit.
• Current international guidance supports selective use with low certainty.
• Success depends on blood flow, infection control, offloading, surgery, treatment completion, and wound severity.
• HBOT does not guarantee closure or prevent every amputation.

This approach gives patients meaningful evidence without replacing uncertainty with a misleading percentage.

Evaluating a Hyperbaric Program’s Reported Success Rate

When a center reports a wound-healing success rate, physicians and hospital leaders should ask:

• Which diagnoses were included?
• Was success defined as complete and sustained closure?
• What was the follow-up period?
• Were patients who discontinued treatment included?
• Were wounds measured consistently?
• Were major and minor amputations reported separately?
• How severe were the wounds at baseline?
• Was revascularization available?
• Were outcomes independently reviewed?
• Were recurrence and mortality reported?

A rate calculated only among patients who completed every treatment will usually appear better than a rate including everyone who began therapy. A program that excludes high-risk patients may also report stronger results than a tertiary center treating the most severe cases.

Transparent outcomes are more valuable than impressive but poorly defined percentages.

A Realistic Interpretation of HBOT Success

HBOT can meaningfully improve healing for selected chronic wounds, particularly some advanced neuro-ischemic or ischemic diabetic foot ulcers. The evidence does not support a single universal success rate.

For diabetic foot ulcers, individual randomized trials have reported complete-healing rates ranging from approximately 20 percent to more than 50 percent in HBOT groups, with comparison groups also varying substantially. Meta-analyses generally favor HBOT for healing, but heterogeneity and trial quality limit confidence in the exact magnitude of benefit. (PubMed)

The most defensible definition of success is not whether a patient completed a predetermined number of chamber sessions. It is whether HBOT contributed to a measurable, durable clinical outcome within a comprehensive wound-care plan.

That outcome may be complete closure, infection remission, successful reconstruction, or preservation of a functional limb. The probability depends less on a generalized percentage than on selecting the right wound, correcting its major barriers, beginning treatment while viable tissue remains, and stopping or revising the plan when objective progress is absent.

How Hyperbaric Oxygen May Support Healing After Delayed Radiation Damage to the Bladder, Bowel, Bone, Skin, and Other Tissues

Radiation therapy is essential to the treatment of many cancers, but its effects are not limited to malignant cells. Normal tissue within or near the treatment field may sustain vascular, cellular, and structural injury that becomes clinically apparent months or years after cancer therapy has ended.

Hyperbaric oxygen therapy, commonly abbreviated as HBOT, is used as an adjunct for selected delayed radiation injuries involving soft tissue or bone. The goal is not to remove radiation from the body or reverse every late effect. HBOT is intended to improve oxygen delivery and support vascular repair within viable tissue that has become chronically hypoxic, fibrotic, fragile, or unable to heal normally.

The Undersea and Hyperbaric Medical Society recognizes delayed radiation injury involving soft tissue and bone as an accepted hyperbaric indication. Medicare also covers osteoradionecrosis and soft tissue radionecrosis when HBOT is used alongside conventional treatment. (UHMS)

Acute and Delayed Radiation Injuries Are Different

Acute radiation effects develop during treatment or shortly afterward. Depending on the treatment field, these may include skin irritation, mucositis, diarrhea, urinary frequency, fatigue, or inflammation.

Delayed radiation tissue injury develops later, sometimes after a long symptom-free interval. It reflects progressive changes within irradiated blood vessels, connective tissue, bone, and organ walls. The tissue may become less vascular, less cellular, more fibrotic, and less able to respond to trauma or infection. (Cochrane)

A minor event may reveal the underlying damage. Examples include:

• A dental extraction followed by exposed jawbone
• A cystoscopy or urinary infection followed by recurrent bladder bleeding
• Surgery within an irradiated field followed by wound breakdown
• Minor trauma followed by chronic ulceration
• Progressive rectal bleeding years after pelvic radiation

HBOT is generally directed toward delayed injury rather than ordinary acute radiation side effects. Acute symptoms still require evaluation by radiation oncology and the relevant organ specialist.

Why Irradiated Tissue May Fail to Heal

Radiation can damage small blood vessels and alter the normal balance of inflammation, fibrosis, and tissue repair. Over time, the affected area may develop reduced capillary density, chronic hypoxia, stromal fibrosis, and limited regenerative capacity.

The resulting tissue may appear intact at rest but fail when placed under additional stress. Surgery, infection, pressure, dental extraction, or mechanical trauma can create an oxygen demand that the damaged circulation cannot meet.

Clinical consequences may include:

• Persistent ulceration
• Recurrent bleeding
• Tissue necrosis
• Fibrosis and restricted movement
• Bone exposure
• Infection
• Fistula formation
• Surgical wound breakdown
• Failure of grafts or flaps

The injury is often progressive. Treating only the visible wound or bleeding vessel may provide temporary control without correcting the underlying vascular deficiency.

How HBOT Supports Radiation Injury Recovery

During HBOT, the patient breathes oxygen while exposed to increased atmospheric pressure. This markedly raises arterial oxygen tension and increases the amount of oxygen dissolved directly in plasma.

The immediate increase in tissue oxygen is temporary. The larger therapeutic objective is to create repeated oxygen exposures that stimulate repair processes within viable irradiated tissue.

Potential effects include:

• Improved oxygen diffusion into hypoxic tissue
• Support for endothelial and fibroblast activity
• Promotion of angiogenic signaling
• Development of new capillary networks
• Improved collagen production and organization
• Support for epithelial repair
• Improved oxygen-dependent immune function
• Greater resistance to recurrent tissue breakdown

HBOT does not remove established scar tissue or restore tissue that is already completely necrotic. Its benefit depends on the presence of viable cells and enough circulation to deliver oxygenated plasma into the injured area. (NCBI)

Radiation Cystitis Has Some of the Strongest Evidence

Radiation cystitis can occur after treatment for prostate, bladder, cervical, endometrial, rectal, or other pelvic cancers.

Patients may experience:

• Visible or microscopic hematuria
• Clot retention
• Urinary frequency
• Urgency
• Dysuria
• Pelvic discomfort
• Incontinence
• Reduced bladder capacity
• Recurrent hospitalization or transfusion

Before symptoms are attributed to radiation, patients generally require a urologic evaluation appropriate to their presentation. Infection, stones, anticoagulation, upper urinary tract disease, recurrent cancer, and a new urothelial malignancy may produce similar symptoms.

HBOT is intended to improve the condition of the bladder wall rather than simply stop bleeding for the duration of one treatment. It is commonly considered after radiation injury has been documented and symptoms remain significant despite appropriate urologic care.

Long-Term Findings From the RICH-ART Trial

The randomized RICH-ART trial compared HBOT with standard care in patients with chronic urinary symptoms after pelvic radiation. Participants assigned to HBOT received 30 to 40 treatments at approximately 2.4 to 2.5 atmospheres absolute for 80 to 90 minutes per session.

The original trial demonstrated significantly greater improvement in patient-reported urinary symptoms after HBOT. Five-year follow-up published in 2025 found that the mean improvement in the urinary symptom score remained stable among the followed patients, supporting the possibility of durable benefit rather than only temporary symptom suppression. (PubMed)

The trial did not represent every patient with hemorrhagic radiation cystitis. It excluded patients with certain severe findings, including recent bleeding requiring substantial transfusion, permanent catheter dependence, bladder capacity below 100 mL, and bladder fistula. Outcomes should therefore not be generalized automatically to patients with a severely contracted, fistulizing, or structurally nonfunctional bladder. (PubMed)

HBOT may reduce hematuria and urinary symptom burden, but some patients still require clot evacuation, fulguration, embolization, urinary diversion, or cystectomy.

Radiation Proctitis and Bowel Dysfunction Require Careful Selection

Pelvic radiation can injure the rectum and lower bowel, producing:

• Rectal bleeding
• Urgency
• Tenesmus
• Mucus discharge
• Diarrhea
• Pain
• Incontinence
• Ulceration
• Stricture or fistula

The evidence for HBOT in lower bowel radiation injury is mixed. The 2023 Cochrane review found some evidence of benefit in selected patients with late radiation injury involving the rectum, but it emphasized small studies, variable methods, and uncertainty about which patients are most likely to respond. (Cochrane)

The sham-controlled HOT2 trial did not demonstrate a significant benefit from HBOT for its primary outcomes in patients with chronic bowel dysfunction after pelvic radiation. This negative trial is important because radiation-related bowel symptoms can result from several different processes, not all of which are likely to respond to increased tissue oxygenation. (PubMed Central (PMC))

A gastroenterology or colorectal evaluation may be needed to distinguish:

• Bleeding telangiectasia
• Ulceration
• Fibrotic stricture
• Fistula
• Malabsorption
• Bile acid dysfunction
• Pelvic floor dysfunction
• Recurrent malignancy
• Inflammatory or infectious disease

HBOT may be more biologically relevant to documented ischemic ulceration or soft tissue radionecrosis than to nonspecific bowel frequency or functional symptoms without clear tissue injury.

Osteoradionecrosis Requires Multidisciplinary Management

Osteoradionecrosis occurs when irradiated bone loses viability and fails to heal. It most commonly affects the mandible after head and neck radiation, although other bones within a treatment field may also be involved.

Potential findings include:

• Exposed bone
• Persistent oral or facial pain
• Drainage
• Swelling
• Pathologic fracture
• Fistula
• Dental instability
• Infection
• Difficulty chewing or swallowing

Management may include oral hygiene, antibiotics when infection is present, limited debridement, removal of sequestra, reconstructive surgery, vascularized tissue transfer, and selected medical therapies.

HBOT has historically been incorporated into protocols for mandibular osteoradionecrosis and dental surgery in irradiated bone. Contemporary guidance is more cautious. The 2024 ISOO-MASCC-ASCO guideline concluded that evidence supporting routine HBOT for prevention or management of jaw osteoradionecrosis remains limited and that its use is largely unjustified as an automatic standard for every patient. (ASCO Publications)

This does not mean HBOT has no role in head and neck radiation injury. It means treatment should be individualized rather than based solely on a history of radiation or a planned dental extraction.

Consultation may still be reasonable when:

• Established bone and soft tissue radionecrosis coexist
• Previous conservative treatment has failed
• A substantial reconstruction is planned
• The wound bed is markedly hypoxic
• The surgeon and hyperbaric physician define a specific objective
• Other reconstructive options are limited

HBOT should not replace removal of necrotic bone, infection management, stabilization of a pathologic fracture, or oncologic evaluation.

Radiation Injury of the Breast and Chest Wall

Breast and chest wall radiation may produce late pain, fibrosis, edema, skin changes, tissue tightness, and reduced shoulder mobility.

A 2024 randomized clinical trial evaluated 30 to 40 HBOT sessions in women with late local effects following breast irradiation. Offering HBOT did not significantly reduce the primary pain outcome in the intention-to-treat analysis, although fibrosis was reduced. Patients who completed treatment showed stronger signals of reduced pain and fibrosis, but only a minority of those offered HBOT completed the course. (PubMed)

These findings highlight two important limitations:

1. Treatment burden can substantially affect participation.
2. Different late effects may respond differently.

Fibrosis, pain, edema, and movement restriction should not be treated as one interchangeable condition. A patient may also need physical therapy, lymphedema treatment, pain management, reconstructive evaluation, or assessment for recurrent cancer.

HBOT may be considered for selected breast or chest wall radiation injuries, but expectations should remain tied to the specific symptom and tissue abnormality being treated.

Skin and Soft Tissue Radionecrosis

Soft tissue radionecrosis may present as chronic ulceration, drainage, pain, bleeding, fibrosis, or wound breakdown within a previous radiation field.

Common sites include:

• Head and neck
• Chest wall
• Pelvis and perineum
• Abdominal wall
• Extremities
• Surgical incisions within irradiated tissue

A new ulcer or mass in a previous cancer field should not automatically be labeled radionecrosis. Evaluation may require imaging, biopsy, cultures, vascular assessment, or specialist review to exclude recurrent malignancy, infection, pressure injury, or another cause.

HBOT may be appropriate when viable irradiated tissue remains but cannot heal because of chronic vascular injury and hypoxia. The visible wound still requires local care, debridement when appropriate, infection management, nutrition, pressure relief, and reconstruction planning.

HBOT Around Surgery in Irradiated Tissue

Surgery within an irradiated field can be difficult because tissue may have limited blood flow, reduced elasticity, and impaired healing capacity.

HBOT may be considered before and after selected operations when the surgical team believes that improving the tissue environment could reduce wound breakdown or support reconstruction. Potential scenarios include:

• Debridement of established radionecrosis
• Reconstruction of a chronic radiation wound
• Grafting or flap placement into irradiated tissue
• Surgery involving both bone and soft tissue injury
• Repair after previous wound failure

The 2023 Cochrane review found low-certainty evidence that HBOT may reduce wound dehiscence following some head and neck soft tissue operations in irradiated patients. The review also emphasized uncertainty regarding optimal patient selection, timing, and dose. (Cochrane)

No universal preoperative and postoperative schedule should be applied to every patient with prior radiation. Historical protocols remain influential, but modern surgery, radiation planning, vascularized reconstruction, and updated guidelines have changed the decision framework.

The surgeon and hyperbaric physician should agree on:

• The diagnosis being treated
• Whether viable tissue remains
• The purpose of preoperative treatment
• The timing of surgery
• The number of postoperative treatments
• Criteria for stopping or modifying the plan

Treatment Protocols Vary by Organ and Objective

Common delayed radiation injury protocols involve treatment once daily, five days per week, at approximately 2.0 to 2.5 atmospheres absolute. Oxygen exposure often lasts 80 to 120 minutes, and many courses involve approximately 30 to 40 sessions.

The RICH-ART protocol used 30 to 40 sessions at 2.4 to 2.5 atmospheres absolute for 80 to 90 minutes. Broader published protocols for soft tissue radionecrosis commonly fall within a similar general range, although treatment may be adjusted for the organ involved, clinical response, surgical plan, and patient tolerance. (PubMed)

A treatment course should not continue automatically because a certain number of sessions was initially authorized. Reassessment should consider:

• Symptom change
• Bleeding frequency
• Wound appearance
• Tissue viability
• Pain and function
• Surgical readiness
• Adverse effects
• Whether the original treatment goal remains achievable

Recovery may become apparent gradually. Angiogenic and reparative changes require repeated exposure and may continue to influence healing after the chamber course ends.

What Recovery May Look Like

Radiation injury recovery does not always mean complete restoration of normal tissue.

Meaningful improvement may include:

• Reduced bladder or rectal bleeding
• Fewer clot-retention episodes
• Reduced transfusion requirements
• Improved urinary frequency or urgency
• Healing of a chronic ulcer
• Improved tissue quality before surgery
• Reduced wound breakdown after reconstruction
• Reduced pain
• Greater tolerance of dental or surgical procedures
• Preservation of tissue or organ function

Some patients experience partial rather than complete improvement. Fibrosis, structural narrowing, fistulas, advanced bone destruction, or severe loss of organ capacity may not resolve with HBOT alone.

The treatment objective should be established before therapy begins so that the patient and clinical team can judge whether meaningful recovery is occurring.

Current Evidence Supports Selective Use

The 2023 Cochrane review included 18 randomized studies with 1,071 participants. It found low- to moderate-certainty evidence that HBOT may improve outcomes in selected late radiation injuries involving the head and neck, bladder, and rectum. It also found possible reductions in wound dehiscence and modest improvement in pain following head and neck radiation. (Cochrane)

The evidence remains limited by:

• Small study populations
• Differences in treated organs
• Variable injury severity
• Different chamber protocols
• Inconsistent outcome definitions
• Limited long-term follow-up
• Difficulty creating a credible sham treatment

Evidence should therefore be interpreted by organ and clinical phenotype. Strong findings in radiation cystitis should not be transferred automatically to bowel dysfunction, mandibular osteoradionecrosis, breast fibrosis, or every chronic symptom following cancer treatment.

HBOT Does Not Treat Recurrent Cancer

HBOT is directed toward normal tissue damaged by radiation. It is not a treatment for residual or recurrent malignancy.

Before therapy, clinicians should investigate suspicious findings such as:

• A new mass
• Progressive ulceration
• Unexplained bleeding
• New bone destruction
• Weight loss
• Enlarging lymph nodes
• Symptoms inconsistent with the expected radiation field

Biopsy may be necessary when recurrent cancer cannot be excluded.

A history of treated cancer does not automatically prohibit HBOT. The decision should involve the relevant oncology team when active disease, ongoing systemic therapy, or uncertainty about recurrence is present.

Safety Screening and Treatment Burden

HBOT is generally well tolerated in qualified medical facilities, but potential adverse effects include:

• Middle-ear or sinus barotrauma
• Temporary nearsightedness
• Claustrophobia
• Blood glucose changes
• Pulmonary pressure injury
• Rare oxygen-induced seizure

The Cochrane review found increased risks of temporary visual-acuity reduction and ear barotrauma in treated patients. (Cochrane)

An untreated pneumothorax must be addressed before pressurization. Significant pulmonary disease, inability to equalize ear pressure, seizure risk, implanted devices, cardiac instability, and medication interactions require individualized assessment.

Treatment burden is also substantial. A course of 30 to 40 weekday sessions may require six to eight weeks of travel and scheduling. The breast-radiation trial demonstrated that many eligible patients declined treatment because of its intensity. (PubMed)

Transportation, work, caregiving, mobility, and cost should be discussed before therapy begins.

Coverage Requires a Documented Radiation Injury

The current Medicare National Coverage Determination includes:

• Osteoradionecrosis as an adjunct to conventional treatment
• Soft tissue radionecrosis as an adjunct to conventional treatment

Medicare does not cover HBOT simply because a patient previously received radiation. The medical record should establish a delayed tissue injury and explain how HBOT supports the broader treatment plan. (Centers for Medicare & Medicaid Services)

Useful documentation may include:

• Cancer diagnosis and treatment history
• Radiation site, dose, and dates
• Symptom timeline
• Cystoscopy, endoscopy, imaging, or operative findings
• Pathology or biopsy results
• Previous conventional treatment
• Evidence excluding recurrence when appropriate
• The specific clinical objective
• Planned surgery or reconstruction
• Serial response during treatment

Commercial payer policies may differ, and prior authorization may be required.

Coordinated Cancer Survivorship Care Is Essential

Delayed radiation injury often crosses specialty boundaries.

Depending on the affected tissue, care may involve:

• Radiation oncology
• Urology
• Gastroenterology
• Colorectal surgery
• Head and neck surgery
• Oral and maxillofacial surgery
• Plastic surgery
• Wound care
• Physical therapy
• Hyperbaric medicine

HBOT is most useful when these teams agree on the diagnosis and treatment endpoint.

For radiation cystitis, HBOT should complement urologic evaluation and bleeding management. For bowel injury, it should follow careful characterization of the cause of symptoms. For osteoradionecrosis, it should be coordinated with dental, surgical, and oncologic care. For reconstructive wounds, chamber treatment should be scheduled around debridement and flap or graft procedures.

HBOT and radiation injury recovery should therefore be understood as part of cancer survivorship medicine. The treatment may help selected tissues develop a more durable blood supply and greater capacity to heal, but it cannot reverse every structural consequence of radiation.

The strongest evidence currently supports careful, organ-specific patient selection, particularly for chronic radiation cystitis. Other applications may be appropriate, but their expected benefits and limitations should be discussed honestly.

Understanding When Hyperbaric Oxygen May Support Limb Salvage and Why It Must Remain Part of a Multidisciplinary Strategy

Preventing amputation is one of the most compelling goals in wound care, vascular medicine, trauma surgery, podiatry, and hyperbaric medicine. Limb loss can profoundly affect mobility, independence, employment, rehabilitation needs, and quality of life.

Hyperbaric oxygen therapy, commonly abbreviated as HBOT, may contribute to amputation reduction in selected patients whose limbs are threatened by hypoxic wounds, acute traumatic ischemia, severe tissue injury, or compromised reconstruction. It is not a universal limb-salvage treatment and should never be presented as an alternative to revascularization, surgical source control, pressure relief, or appropriate amputation when an unsalvageable limb threatens the patient’s life.

The most accurate clinical position is that HBOT may improve tissue preservation and wound healing in carefully selected patients. Whether those effects reliably reduce major amputation remains dependent on the diagnosis, severity, timing, standard care, and quality of the available evidence.

Amputation Reduction Is a System Outcome

An amputation is rarely caused by insufficient tissue oxygen alone. Most threatened limbs involve several interacting problems, such as:

• Peripheral arterial disease
• Neuropathy
• Infection
• Osteomyelitis
• Tissue necrosis
• Repetitive pressure
• Severe edema
• Traumatic vascular injury
• Delayed presentation
• Metabolic disease
• Inadequate access to specialty care

The CDC reports that lower-limb amputations are increasing in the United States and that complications associated with diabetes account for a substantial share of these procedures. It also identifies vascular disease, neuropathy, infection, delayed wound recognition, and unequal access to care as important contributors. (CDC)

This means no single technology can be credited with reducing amputations across an entire population. Effective limb preservation generally requires coordinated vascular assessment, infection control, debridement, offloading, metabolic management, reconstructive care, rehabilitation, and selected adjunctive treatments.

HBOT should be understood as one component of that system.

How HBOT May Support Limb Preservation

During HBOT, the patient breathes oxygen while exposed to increased atmospheric pressure. This substantially increases arterial oxygen tension and the amount of oxygen dissolved directly in plasma.

Oxygen-rich plasma can diffuse farther from functioning capillaries into hypoxic tissue. This may be helpful when edema, inflammation, microvascular injury, or impaired red blood cell passage limits ordinary oxygen delivery.

Potentially relevant effects include:

• Increased oxygen availability in viable hypoxic tissue
• Support for fibroblast activity and collagen deposition
• Promotion of angiogenic signaling
• Improved oxygen-dependent leukocyte activity
• Reduction of selected forms of edema
• Modulation of ischemia-reperfusion injury
• Support for demarcation and preservation of marginal tissue

These effects can improve the environment in which tissue heals, but they require some remaining circulation. HBOT cannot deliver an adequate oxygen dose to tissue with no functional blood supply.

It also cannot restore tissue that is already irreversibly necrotic.

Diabetic Foot Ulcers Are the Primary Amputation-Reduction Population

Most discussion of HBOT and amputation reduction concerns diabetes-related foot ulcers.

Diabetes can increase limb-loss risk through the combined effects of neuropathy, peripheral arterial disease, impaired healing, infection, and delayed recognition of tissue damage. A small wound can progress into a deep ulcer, abscess, osteomyelitis, gangrene, or systemic infection when these problems are not corrected promptly. (CDC)

HBOT is not indicated for every diabetic foot ulcer. The strongest clinical and coverage frameworks focus on advanced, limb-threatening wounds that have not responded adequately to comprehensive standard care.

Medicare currently covers adjunctive HBOT for a diabetes-related lower-extremity wound when all three of the following conditions are met:

1. The patient has type 1 or type 2 diabetes.
2. The wound is classified as Wagner grade III or higher.
3. The wound has failed an adequate course of standard therapy.

Coverage begins only after at least 30 days without measurable healing and requires continued standard wound management during the HBOT course. (Centers for Medicare & Medicaid Services)

Wagner Grade Matters, but It Is Not the Entire Assessment

The Wagner system describes diabetic foot ulcer depth and the presence of deeper infection or gangrene.

In simplified terms:

• Grade I involves a superficial ulcer.
• Grade II extends into deeper structures.
• Grade III involves deep infection, abscess, or osteomyelitis.
• Grade IV involves localized gangrene.
• Grade V involves extensive gangrene of the foot.

Higher grades generally indicate greater limb threat, but Wagner classification does not describe every factor influencing salvage. It does not fully capture ischemia severity, infection severity, wound location, tissue perfusion, patient frailty, renal disease, or reconstructive options.

The decision to use HBOT should therefore combine wound grade with vascular, surgical, infectious, and functional assessments.

Current Guidelines Are Supportive but Cautious

The 2023 International Working Group on the Diabetic Foot guideline conditionally recommends considering systemic HBOT for neuro-ischemic or ischemic diabetes-related foot ulcers when standard care alone has failed and the resources needed to provide treatment already exist. The recommendation is based on low-certainty evidence.

Importantly, the guideline found that better-quality studies suggested possible benefits in wound healing and ulcer-area reduction, but it concluded that strong evidence of amputation prevention was lacking. It also noted major differences among studies in ischemia severity, outcome definitions, follow-up periods, and treatment methods. (IWGDF Guidelines)

Earlier UHMS guidance was more favorable, suggesting HBOT for Wagner grade III or higher wounds that failed to improve after 30 days of standard care, with the objective of reducing major amputation and incomplete healing. (Guideline Central)

These positions are not necessarily contradictory. They reflect different evidence-review methods, publication dates, and thresholds for making recommendations.

Why Meta-Analyses Reach Different Conclusions

Several meta-analyses have reported lower amputation rates or higher healing rates with adjunctive HBOT. A 2024 review organized by Wagner grade reported lower minor amputation rates in grade III ulcers and lower major amputation rates in grade IV ulcers. (PubMed Central (PMC))

Other analyses have also concluded that HBOT may reduce major amputation when added to standard care. (PubMed Central (PMC))

These findings are encouraging, but they should not be interpreted as definitive proof that HBOT independently prevents amputation in routine practice. Meta-analysis cannot fully correct weaknesses in the studies it combines.

Common limitations include:

• Small study populations
• Inconsistent wound classifications
• Variable ischemia severity
• Different HBOT pressures and schedules
• Incomplete reporting of revascularization
• Differences in offloading and infection control
• Variation in how amputation was defined
• Limited blinding
• High risk of selection bias
• Short or inconsistent follow-up

The IWGDF guideline therefore reached a more restrained conclusion despite reviewing multiple trials. It found possible healing benefits but insufficient reliable evidence for amputation reduction as a distinct outcome.

Major and Minor Amputation Should Not Be Combined Carelessly

Amputation studies frequently distinguish between minor and major procedures.

A minor amputation may remove a toe, ray, or portion of the foot while preserving a functional limb. A major amputation generally occurs at or above the ankle and carries greater implications for mobility and prosthetic rehabilitation.

These outcomes should not automatically be treated as equivalent.

A limited toe or ray amputation may be part of successful limb salvage when it removes infected or nonviable tissue and allows the remaining foot to heal. Avoiding every minor amputation is not always an appropriate clinical objective.

A more meaningful goal may be:

• Preventing progression to below-knee or above-knee amputation
• Preserving a plantigrade, functional foot
• Maintaining the ability to transfer or walk
• Limiting the level of tissue removal
• Achieving durable wound closure
• Preventing recurrent sepsis or hospitalization

Research reports should identify the level and purpose of amputation rather than presenting all procedures as the same adverse outcome.

Revascularization Comes Before Hyperbaric Treatment

A threatened diabetic limb requires vascular assessment. This may include pulse examination, ankle pressures, toe pressures, Doppler waveforms, transcutaneous oxygen testing, duplex imaging, CT angiography, conventional angiography, or another appropriate study.

When significant correctable arterial disease is present, endovascular or open revascularization may be required.

Global vascular guidelines emphasize revascularization planning, medical therapy, surveillance, and multidisciplinary care for chronic limb-threatening ischemia. They state that the effectiveness of nonrevascularization therapies, including HBOT, has not been established as a replacement for restoring blood flow. (PubMed)

HBOT should not be used to postpone vascular consultation or create the appearance that an ischemic wound is being treated while the underlying arterial obstruction remains unaddressed.

The treatment may become relevant after:

• Revascularization has restored the best achievable inflow
• No additional vascular intervention is technically possible
• Residual microvascular hypoxia continues to threaten healing
• The patient otherwise meets a recognized indication

CMS similarly requires assessment and correction of vascular problems when possible as part of standard diabetic wound care before and during HBOT. (Centers for Medicare & Medicaid Services)

Infection Requires Source Control

Deep infection, abscess, necrotizing tissue, and osteomyelitis are major drivers of amputation.

HBOT may support leukocyte activity and tissue oxygenation, but it cannot drain an abscess, remove infected bone, or debride necrotic tissue.

Limb-salvage care may require:

• Urgent incision and drainage
• Surgical debridement
• Bone resection
• Culture-directed antimicrobial therapy
• Removal or revision of infected hardware
• Staged reconstruction
• Minor amputation to control infection

The IWGDF infection guideline advises against using HBOT when the sole objective is treatment of a diabetes-related foot infection because evidence for infection control itself is limited. The potential indication is the qualifying wound and its healing environment, not infection in isolation. (IWGDF Guidelines)

A patient with advancing sepsis or necrotizing infection needs surgery and resuscitation before chamber scheduling.

Offloading Is a Limb-Salvage Intervention

Neuropathic foot wounds often remain open because the injured area continues to bear pressure during standing and walking.

HBOT cannot compensate for persistent mechanical trauma. Even a well-oxygenated wound may fail when it is repeatedly compressed or sheared.

The care plan may require:

• Total-contact casting
• A removable cast walker
• Custom footwear
• Postoperative offloading
• Assistive devices
• Activity modification
• Correction of deformity in selected patients

CMS includes appropriate offloading among the standard-care requirements that must continue during HBOT. (Centers for Medicare & Medicaid Services)

Poor adherence should be addressed compassionately. Transportation, work, caregiving responsibilities, housing conditions, cognitive impairment, and the practical difficulty of using an offloading device may all affect adherence.

Acute Trauma Creates a Different Limb-Salvage Pathway

HBOT may also support amputation reduction in selected crush injuries, severe open fractures, compartment syndromes, replantations, and acute traumatic peripheral ischemia.

The treatment rationale involves increasing oxygen delivery to marginally perfused tissue, reducing edema, and limiting secondary ischemia-reperfusion injury. As in chronic wounds, HBOT must not delay hemorrhage control, vascular repair, fracture stabilization, fasciotomy, or debridement.

The international HOLLT randomized trial studied HBOT in severe lower-limb trauma. The combined primary outcome of acute infection or necrosis was lower in the HBOT group but did not reach statistical significance. Tissue necrosis considered separately occurred less frequently with HBOT, while acute infection did not differ significantly. (PubMed Central (PMC))

The trial supports a potential tissue-preservation benefit, but it was not definitive evidence that HBOT reduces traumatic amputation across all injury patterns. Injury severity, vascular disruption, contamination, reconstruction, and timing remain decisive.

Medicare recognizes acute traumatic peripheral ischemia and crush injuries as covered indications when function, limb, or life is threatened. (Centers for Medicare & Medicaid Services)

Compromised Reconstructions May Affect Amputation Risk

A failed graft, flap, replantation, or soft-tissue reconstruction can expose bone, vessels, tendon, hardware, or a previously closed amputation site. Loss of coverage may convert a salvageable limb into one requiring more extensive tissue removal.

HBOT may be considered when reconstructive tissue is hypoxic but viable after mechanical and vascular causes have been corrected.

The surgeon must first evaluate for:

• Arterial or venous thrombosis
• Pedicle kinking
• Hematoma
• Seroma
• Excessive pressure
• Infection
• Graft displacement
• Inadequate recipient-bed preparation

Medicare covers preparation and preservation of compromised skin grafts but not HBOT for the primary management of ordinary wounds. (Centers for Medicare & Medicaid Services)

Successful preservation of coverage may indirectly reduce amputation risk, but the clinical endpoint should be documented as graft or flap salvage rather than assuming that every successful reconstruction prevented a major amputation.

Patient Selection Determines Whether HBOT Can Help

The best candidates have a defined oxygen-responsive problem and enough viable tissue remaining to change the outcome.

Features that may support referral include:

• An advanced diabetes-related foot ulcer
• Ischemic or neuro-ischemic wound physiology
• Failure of comprehensive standard care
• Corrected or maximally treated arterial disease
• Adequate source control
• A salvageable foot or limb
• A realistic functional objective
• Ability to complete a prolonged treatment schedule

HBOT is less likely to change the outcome when:

• The limb is irreversibly necrotic
• Uncontrolled sepsis requires immediate amputation
• Revascularization is needed but has not been pursued
• Mechanical pressure remains uncorrected
• The wound is superficial and otherwise healing
• The patient cannot complete treatment safely
• Continued limb salvage would leave a painful, nonfunctional extremity
• Treatment would delay a necessary operation

Limb preservation should not become an absolute goal when amputation offers the safest path to infection control, wound closure, pain relief, or functional rehabilitation.

Treatment Requires Repeated Exposure

A chronic wound course commonly involves daily treatment, often five days per week, over several weeks. The pressure, duration, oxygen periods, air breaks, and total number of treatments should be prescribed by a qualified hyperbaric physician.

The course should not be treated as an automatic block of visits.

Clinical reassessment should consider:

• Wound dimensions
• Tissue quality
• Granulation
• Drainage
• Necrosis
• Infection
• Vascular status
• Offloading adherence
• Need for further surgery
• Overall functional plan

CMS requires reassessment at least every 30 days and does not support continued coverage when measurable healing has not occurred during a treatment interval. (Centers for Medicare & Medicaid Services)

A wound that continues to deteriorate needs diagnostic and surgical reassessment, not simply more chamber sessions.

Amputation-Free Survival Is a Better Long-Term Measure

A program should not evaluate success only by asking whether an amputation occurred during the HBOT course.

More meaningful measures include:

• Major amputation-free survival
• Time to durable wound closure
• Recurrence after healing
• Rehospitalization
• Repeat debridement
• Functional walking status
• Preservation of an independently usable limb
• Mortality
• Patient-reported quality of life

A limb may remain attached but provide little function, remain chronically infected, or require repeated hospitalization. Conversely, a minor amputation may allow durable healing and preserve mobility.

Outcome reporting should reflect these distinctions.

Risks and Treatment Burden Matter

HBOT is generally well tolerated in appropriately selected patients, but it is not risk free.

Potential adverse effects include:

• Middle-ear or sinus barotrauma
• Claustrophobia
• Blood glucose changes
• Temporary visual changes
• Pulmonary pressure injury
• Rare oxygen-induced seizure

Patients with advanced diabetic wounds may also have heart failure, kidney disease, frailty, pulmonary disease, limited mobility, or unstable glucose levels. The IWGDF guideline specifically notes that comorbidity and frailty can affect suitability for treatment.

The practical burden can be considerable. Daily transportation, time away from work or caregiving, dressing coordination, and prolonged offloading can make completion difficult. These barriers should be assessed before treatment begins.

Limb Salvage Requires Equity and Early Access

Amputation risk is influenced by more than biology.

The CDC reports substantial geographic and racial differences in diabetes-related lower-limb amputations. It also identifies transportation, income, health literacy, access to care, and other social determinants as contributors to unequal outcomes. (CDC)

A technically advanced HBOT program cannot reduce population-level amputations when patients reach vascular, podiatric, or wound specialists only after extensive gangrene or infection has developed.

Effective prevention requires:

• Early foot screening
• Rapid referral for new ulcers
• Access to vascular assessment
• Timely infection treatment
• Affordable offloading
• Transportation support
• Patient education
• Coordination across specialties

HBOT should be added to this pathway rather than used as a substitute for it.

A Balanced Clinical Interpretation

The evidence supports neither of two extreme claims.

It is inaccurate to say that HBOT has no potential role in amputation reduction. Several randomized studies, clinical guidelines, and meta-analyses suggest that selected advanced diabetic wounds and traumatic ischemic injuries may benefit from adjunctive treatment. (PubMed Central (PMC))

It is also inaccurate to claim that HBOT reliably prevents amputation in every patient with a diabetic wound or threatened limb. The current IWGDF guideline considers the certainty of evidence low and states that strong evidence of amputation prevention is lacking.

The most defensible position is selective use.

HBOT may improve the probability of limb preservation when:

1. The diagnosis is appropriate.
2. The limb remains salvageable.
3. Blood flow has been evaluated and optimized.
4. Infection and necrosis have been treated surgically.
5. Offloading and metabolic care are active.
6. Treatment begins before irreversible tissue loss.
7. Progress is measured objectively.
8. The clinical team is willing to stop or revise the plan when benefit is not occurring.

HBOT does not save limbs by itself. It may strengthen a coordinated limb-preservation strategy by supporting viable hypoxic tissue during the period in which vascular, surgical, infectious, and wound-care interventions are working.

When to Refer Patients With Radiation Cystitis, Hemorrhagic Cystitis, Pelvic Radiation Injury, Fournier Gangrene, and Compromised Urologic Reconstruction

Hyperbaric oxygen therapy, commonly abbreviated as HBOT, has a focused role within urology. Its most established urologic application is delayed radiation injury of the bladder, particularly radiation cystitis associated with hematuria, urinary frequency, urgency, dysuria, and reduced quality of life.

HBOT may also be relevant when a urologist is managing necrotizing infection, compromised reconstructive tissue, or another recognized hyperbaric condition. It is not a general treatment for lower urinary tract symptoms, recurrent urinary infection, erectile dysfunction, interstitial cystitis, postoperative discomfort, or uncomplicated surgical healing.

A useful referral identifies a specific tissue problem that increased oxygen delivery may help correct. The Undersea and Hyperbaric Medical Society recognizes delayed radiation injury involving soft tissue or bone as an accepted HBOT indication. Medicare separately covers soft tissue radionecrosis and osteoradionecrosis when HBOT is used as an adjunct to conventional treatment. (UHMS)

Radiation Cystitis Is the Primary Urologic Referral Indication

Pelvic radiation can produce progressive injury to the bladder months or years after cancer treatment. The affected tissue may become hypovascular, fibrotic, fragile, and chronically hypoxic.

Radiation cystitis may occur after treatment for:

• Prostate cancer
• Bladder cancer
• Cervical or endometrial cancer
• Rectal or anal cancer
• Other pelvic malignancies

Patients may present with:

• Microscopic or visible hematuria
• Clot retention
• Urinary frequency
• Urgency
• Dysuria
• Pelvic or bladder pain
• Reduced bladder capacity
• Incontinence
• Recurrent admissions or transfusion requirements

HBOT is intended to address the underlying radiation tissue injury rather than merely suppressing bleeding temporarily. Increased tissue oxygenation may support angiogenic signaling, capillary development, fibroblast activity, epithelial repair, and recovery of viable hypoxic tissue.

Do Not Attribute Hematuria to Radiation Without Evaluation

A previous history of pelvic radiation does not establish that new hematuria is caused by radiation cystitis.

Patients who received pelvic radiation remain at risk for urothelial malignancy and may also develop infection, stones, upper tract disease, renal pathology, prostatic bleeding, or anticoagulation-associated hemorrhage.

The 2025 AUA/SUFU microhematuria guideline identifies prior pelvic radiation as an additional urothelial cancer risk factor. It recommends risk-based evaluation, with cystoscopy and axial upper tract imaging for patients classified as high risk. (American Urological Association)

Before referring a patient for HBOT, the urologist should generally document an evaluation appropriate to the patient’s presentation and malignancy risk. This may include:

• Urinalysis and urine culture
• Complete blood count
• Renal function
• Cystoscopy
• Upper tract imaging
• Urine cytology in selected circumstances
• Biopsy of suspicious bladder lesions
• Review of anticoagulant or antiplatelet therapy

Cystoscopic findings associated with radiation injury may include telangiectasia, friable mucosa, diffuse erythema, ulceration, and bleeding from multiple surfaces. Suspicious focal lesions should be evaluated for recurrent or new malignancy rather than presumed to be radiation change.

Stabilize Severe Hemorrhage Before Outpatient Referral

A patient with active clot retention, hemodynamic instability, symptomatic anemia, obstructive uropathy, or uncontrolled gross hematuria requires immediate urologic and hospital management.

Initial treatment may include:

• Large-bore urethral catheter placement
• Manual clot evacuation
• Continuous bladder irrigation
• Cystoscopy with clot evacuation
• Fulguration of bleeding sites
• Transfusion when clinically indicated
• Reversal or adjustment of anticoagulation
• Upper tract decompression when necessary
• Angiographic embolization in selected refractory cases

HBOT is not an emergency substitute for relieving urinary obstruction or stabilizing blood loss. A bladder filled with clot still requires drainage, and a patient in hemorrhagic shock still requires resuscitation and bleeding control.

Hyperbaric consultation may occur during the hospitalization, especially when the bleeding appears radiation related and is likely to recur. The patient does not necessarily need to remain free of all visible hematuria before consultation, but the airway, circulation, bladder drainage, and immediate hemorrhagic risk must be manageable within the receiving facility’s capabilities.

Refer Before Repeated Bleeding Causes Major Morbidity

HBOT is sometimes considered only after numerous admissions, transfusions, endoscopic procedures, and intravesical treatments. This may delay treatment until the bladder has developed advanced fibrosis, reduced capacity, fistula, or extensive irreversible injury.

Earlier referral may be reasonable when:

• Radiation cystitis has been confirmed
• Hematuria recurs after cystoscopic management
• Urinary symptoms remain clinically significant
• The patient requires repeated irrigation or hospitalization
• Bleeding is producing anemia
• Conventional treatment provides only temporary relief
• The urologist wants to preserve the bladder before more destructive intervention
• The tissue appears viable enough to undergo vascular repair

The Canadian Urological Association best practice report recommends considering HBOT relatively early after cystoscopy and fulguration have failed, noting its ability to address the underlying ischemic process and the body of evidence supporting symptom improvement. (PubMed Central (PMC))

Referral should not be postponed solely because the patient has not tried every possible intravesical agent. Treatment sequencing should account for bleeding severity, local resources, contraindications, patient preferences, and the relative durability and morbidity of available interventions.

How HBOT May Improve Radiation-Damaged Bladder Tissue

During HBOT, the patient breathes oxygen at increased atmospheric pressure. This raises arterial oxygen tension and substantially increases oxygen dissolved in plasma.

Repeated hyperoxic exposures may stimulate vascular and reparative responses in chronically hypoxic radiation-damaged tissue. The intended effects include:

• Increased oxygen diffusion into injured bladder tissue
• Promotion of neovascularization
• Support for fibroblast and epithelial activity
• Improved collagen organization
• Reduction of selected inflammatory processes
• Improved tissue resistance to recurrent bleeding
• Support for healing after cystoscopic or reconstructive intervention

The objective is not simply to constrict bleeding vessels for the duration of a treatment. Hyperoxic vasoconstriction may temporarily reduce edema or bleeding, but the longer-term therapeutic rationale involves recovery of the microvascular environment.

This distinction helps explain why treatment usually requires a series of daily sessions rather than one isolated exposure.

Evidence From the RICH-ART Trial

The RICH-ART trial was a randomized, controlled, phase 2 to 3 study conducted at five Nordic university hospitals. It enrolled patients with persistent urinary symptoms after pelvic radiation and compared HBOT with standard care.

Patients assigned to HBOT received 30 to 40 sessions at approximately 2.4 to 2.5 atmospheres absolute for 80 to 90 minutes per treatment. At follow-up, the improvement in the EPIC urinary score was significantly greater in the HBOT group than in the standard-care group. Transient grade 1 or 2 adverse events involving vision or hearing were reported during treatment. (PubMed)

The five-year RICH-ART follow-up, published in 2025, found that patient-reported improvement in urinary symptoms was sustained over five years among the followed cohort. This provides important evidence that benefit can persist beyond the immediate treatment period. (The Lancet)

These results support HBOT for appropriately selected patients with chronic radiation cystitis. They do not establish equal benefit for every severity or clinical phenotype.

Understand Who Was Not Represented in RICH-ART

The RICH-ART trial excluded several patients frequently encountered in tertiary urologic practice.

Exclusions included:

• Ongoing bleeding requiring more than 500 mL of transfused blood during the previous four weeks
• A permanent urinary catheter
• Bladder capacity below 100 mL
• A bladder fistula
• Previous HBOT for late radiation injury

The trial therefore provides strong information about symptomatic chronic radiation cystitis but less direct guidance for patients with uncontrolled transfusion-dependent hemorrhage, a severely contracted bladder, chronic catheter dependence, or fistulizing disease. (PubMed)

HBOT may still be discussed in severe cases, but expectations should be cautious. Advanced structural damage may require embolization, urinary diversion, reconstructive surgery, or cystectomy. Treatment should not be presented as a reliable method of reversing a fibrotic, nonfunctional bladder.

Registry Data Support Improvement in Real-World Practice

Prospective data from the UHMS Multicenter Registry have also evaluated patient-reported outcomes after HBOT for radiation cystitis.

A 2024 Journal of Urology study examined changes in hematuria, urinary distress, and quality of life among patients treated at multiple centers. Patients underwent a median of approximately 39 sessions and reported improvements in hematuria, urinary function, and quality of life. (PubMed)

Registry data are valuable because they reflect broader clinical practice, including patients treated outside a randomized trial. They cannot fully control for selection bias, concurrent interventions, natural symptom variation, or differences among treatment protocols.

The combined evidence supports HBOT as a reasonable option for selected radiation cystitis patients while reinforcing the need for careful diagnosis and realistic outcome measurement.

Suggested Timing of Referral

Urologists should consider three broad referral pathways.

Urgent inpatient consultation may be appropriate when recurrent radiation bleeding continues after clot evacuation and stabilization, particularly if the patient is facing repeated transfusion, embolization, diversion, or cystectomy.

Early outpatient consultation may be appropriate after confirmation of radiation cystitis when hematuria or lower urinary tract symptoms remain clinically meaningful despite initial urologic treatment.

Planned perioperative consultation may be appropriate when a reconstructive operation is being considered within severely irradiated pelvic or perineal tissue and the team believes tissue oxygenation may affect healing.

Early referral does not mean that every patient will be accepted for treatment. It allows the hyperbaric physician to review the diagnosis, expected benefit, chamber safety, and timing before the disease reaches a less salvageable stage.

HBOT Protocols for Radiation Cystitis

Common protocols use approximately 2.0 to 2.5 atmospheres absolute for 80 to 120 minutes, usually once daily, five days per week.

A treatment course may include approximately 30 to 40 sessions, although the final number depends on:

• Clinical response
• Bleeding frequency
• Urinary symptom improvement
• Treatment tolerance
• The extent of radiation damage
• Planned surgery
• Recurrence during or after treatment

The RICH-ART protocol used 30 to 40 sessions at 240 to 250 kPa for 80 to 90 minutes. (PubMed)

The hyperbaric physician should prescribe the pressure, oxygen periods, air breaks, and number of treatments. The urologist should continue to monitor hematuria, catheter needs, hemoglobin, bladder function, and the possibility of another underlying diagnosis.

Coordinate HBOT With Urologic Procedures

HBOT should be integrated with urologic management rather than treated as a transfer of care.

The urologist may still need to provide:

• Repeat cystoscopy
• Clot evacuation
• Fulguration
• Catheter management
• Intravesical treatment
• Upper tract evaluation
• Management of obstruction
• Surveillance for malignancy
• Embolization referral
• Reconstructive planning

Communication is particularly important when an operation is scheduled during the treatment course. The teams should agree on whether HBOT is intended to prepare irradiated tissue before surgery, support healing afterward, or treat an established radiation injury independent of the operation.

A scheduled chamber treatment should not delay urgent cystoscopy, relief of obstruction, or control of active hemorrhage.

Pelvic Soft Tissue Radionecrosis Beyond the Bladder

Pelvic radiation injury may involve more than the bladder mucosa. Urologists may encounter:

• Perineal wounds
• Urethral tissue injury
• Pelvic soft tissue necrosis
• Nonhealing suprapubic or surgical wounds
• Radiation-damaged tissue surrounding urinary diversion
• Combined bladder and rectal injury
• Wounds involving previously irradiated genital tissue

HBOT may be considered when a documented soft tissue radionecrosis is contributing to poor healing and viable tissue remains. Medicare lists soft tissue radionecrosis as a covered condition when HBOT is used as an adjunct to conventional treatment. (Centers for Medicare & Medicaid Services)

A fistula, ureteral obstruction, urethral stricture, or severely contracted bladder should not be expected to resolve solely through HBOT. These structural problems require diagnosis-specific surgical or reconstructive management.

Fournier Gangrene Requires Surgery Before Chamber Treatment

Fournier gangrene is a necrotizing soft tissue infection involving the perineum, genitalia, or lower abdominal wall. It is a surgical emergency.

Management requires:

• Immediate resuscitation
• Broad-spectrum antimicrobial therapy
• Urgent and extensive debridement
• Repeated operative inspection
• Critical care
• Management of diabetes, renal dysfunction, and shock

HBOT may be considered as an adjunct when it can be delivered without delaying initial or repeat debridement. Medicare covers progressive necrotizing infections, including necrotizing fasciitis, within its national HBOT policy. (Centers for Medicare & Medicaid Services)

A patient should not be transferred away from timely surgical care solely to reach a chamber. Referral is most appropriate when source control has started, the patient can be transported safely, and the receiving hospital can maintain the required surgical and critical-care capability.

Compromised Urologic Grafts and Flaps

Urologists involved in genital, perineal, urethral, or urinary reconstruction may encounter compromised tissue after grafting or flap placement.

Possible referral scenarios include:

• A threatened skin graft after genital reconstruction
• A compromised perineal flap
• Ischemic tissue following urethral reconstruction
• Reconstruction within a heavily irradiated field
• Tissue loss after debridement of Fournier gangrene
• A threatened flap covering urinary or pelvic structures

The operating surgeon must first evaluate for hematoma, seroma, infection, excessive tension, arterial insufficiency, venous congestion, or mechanical disruption.

HBOT is not indicated for a graft or flap that is healing normally. Medicare covers preparation and preservation of compromised skin grafts, specifically distinguishing this use from primary management of ordinary wounds. (Centers for Medicare & Medicaid Services)

The hyperbaric referral should describe the operation, tissue used, vascular status, signs of compromise, corrective procedures already performed, and the specific reconstruction being preserved.

Non-Radiation Hemorrhagic Cystitis

Hemorrhagic cystitis can also follow:

• Cyclophosphamide or ifosfamide
• Hematopoietic stem cell transplantation
• BK virus
• Adenovirus
• Other infectious or chemical injuries

The evidence for HBOT in these settings is substantially less established than the evidence for radiation cystitis. A 2024 retrospective report described HBOT alongside conventional supportive treatment in 16 patients with late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation, but this small nonrandomized study cannot define standard practice. (PubMed)

Referral may be discussed for an exceptional refractory case, but the urologist should clearly identify the cause and recognize that:

• The indication may be investigational
• Insurance coverage may not apply
• Infection-directed or hematologic treatment remains essential
• The expected benefit is less certain
• The protocol may not be standardized

Non-radiation cystitis should not be coded or documented as soft tissue radionecrosis merely to obtain coverage.

Conditions That Do Not Routinely Warrant HBOT Referral

HBOT is not established as routine care for:

• Interstitial cystitis or bladder pain syndrome
• Chronic prostatitis or chronic pelvic pain
• Recurrent uncomplicated urinary tract infection
• Overactive bladder
• Stress or urge incontinence
• Benign prostatic hyperplasia
• Erectile dysfunction
• Peyronie disease
• Uncomplicated postoperative healing
• Routine recovery after prostatectomy
• An uncomplicated urethral reconstruction
• A healthy graft or flap
• General pelvic inflammation

The presence of pelvic pain, urinary frequency, or poor wound healing does not automatically indicate radiation tissue necrosis or another oxygen-responsive condition.

A hyperbaric physician may still provide consultation when the diagnosis is uncertain, but referral should not promise treatment before eligibility has been assessed.

Information to Include With the Referral

A complete referral reduces delays and helps the hyperbaric team assess medical necessity.

Include:

• The suspected hyperbaric diagnosis
• The clinical objective
• Cancer and radiation history
• Radiation field, dose, and treatment dates when available
• Hematuria onset and severity
• Transfusion and hospitalization history
• Cystoscopy findings
• Pathology and cytology
• Upper tract imaging
• Urine culture results
• Previous fulguration or intravesical therapy
• Current catheter or irrigation requirements
• Bladder capacity when known
• Presence of fistula, obstruction, or hydronephrosis
• Anticoagulant and antiplatelet therapy
• Planned urologic procedures

For compromised reconstruction, include the operative report, current photographs, perfusion findings, and details of any surgical revision.

For Fournier gangrene, direct physician-to-physician communication should address debridement status, hemodynamics, ventilatory support, planned return to the operating room, and whether the receiving center can manage the patient’s acuity.

Hyperbaric Safety Screening

The hyperbaric team will conduct its own evaluation, but the urologist should identify factors that may affect treatment.

Relevant issues include:

• Known or suspected pneumothorax
• Severe pulmonary air trapping
• Uncontrolled seizure disorder
• Ear or sinus disease
• Heart failure or significant fluid overload
• Unstable cardiovascular status
• Implanted medical devices
• Insulin or glucose-lowering treatment
• Severe claustrophobia
• Mechanical ventilation
• Continuous infusions
• Pregnancy

Catheters, drainage bags, nephrostomy tubes, ostomy appliances, dressings, and implanted devices require chamber-specific planning. The need for a urinary catheter does not automatically preclude HBOT, but the tubing and collection system must be managed safely during compression and decompression.

Coverage and Documentation

Medicare covers HBOT for soft tissue radionecrosis and osteoradionecrosis when used as an adjunct to conventional treatment. It also covers progressive necrotizing infection and preservation of compromised skin grafts. (Centers for Medicare & Medicaid Services)

Radiation cystitis is typically treated under the soft tissue radionecrosis category when the diagnosis and treatment rationale are documented appropriately.

The medical record should establish:

• Previous therapeutic radiation exposure
• Delayed tissue injury within the radiation field
• Symptoms and objective findings
• Exclusion of recurrent malignancy and other causes when appropriate
• Conventional treatment already provided
• The clinical objective of HBOT
• Ongoing response and medical necessity

Commercial payer policies, prior-authorization requirements, and accepted diagnosis codes vary. The hyperbaric center should verify the patient’s specific benefits rather than assuming that all radiation-associated urinary symptoms qualify.

Measure Outcomes That Matter to Urologic Care

The treatment plan should define what improvement would justify continuing HBOT.

Possible outcomes include:

• Resolution or reduction of visible hematuria
• Fewer clot-retention episodes
• Reduced transfusion requirement
• Improved urinary frequency or urgency
• Reduced dysuria
• Improved patient-reported urinary function
• Fewer hospital admissions
• Successful healing of irradiated tissue
• Preservation of a graft or flap
• Avoidance or postponement of diversion or cystectomy

Improvement should be evaluated over time rather than judged solely by urine appearance on one treatment day.

Some patients experience partial improvement rather than complete resolution. A reduction in hospitalization, transfusion, or procedural burden may still be clinically meaningful.

Continue Urologic Follow-Up After HBOT

Completion of HBOT does not eliminate the need for urologic surveillance.

Patients may require follow-up for:

• Recurrent hematuria
• Malignancy surveillance
• Bladder capacity and storage symptoms
• Upper tract obstruction
• Infection
• Catheter dependence
• Incontinence
• Fistula
• Late reconstructive needs

Symptoms may recur, and selected patients may be considered for additional HBOT after reassessment. The five-year RICH-ART findings indicate that improvement can remain durable, but not every patient maintains complete symptom control indefinitely. (The Lancet)

The best referrals occur after the urologist has confirmed or strongly characterized the disease process, addressed immediate threats, and identified a clear treatment objective. For radiation cystitis, referral should occur before repeated bleeding and fibrosis leave the bladder with little recoverable function.

HBOT is most effective as part of coordinated urologic care. It can support vascular recovery in radiation-damaged tissue, but it cannot replace clot evacuation, cancer evaluation, infection treatment, reconstruction, diversion, or other definitive management when those interventions are required.

When to Request Hyperbaric Consultation for Compromised Reconstructions, Acute Trauma, Infection, Radiation Injury, and Complex Wounds

Hyperbaric oxygen therapy, commonly abbreviated as HBOT, is most useful to surgeons when it addresses a defined threat to tissue viability, infection control, or postoperative healing. It is not a routine method for accelerating recovery after an uncomplicated operation.

A referral should identify the specific surgical problem that HBOT may help address. Examples include a compromised flap that remains viable after correction of a mechanical cause, acute traumatic ischemia following revascularization, chronic refractory osteomyelitis after appropriate source control, or surgery within tissue damaged by radiation.

The Undersea and Hyperbaric Medical Society, or UHMS, recognizes several surgical and perioperative applications of HBOT, including compromised grafts and flaps, crush injury and acute traumatic ischemia, necrotizing soft tissue infection, refractory osteomyelitis, delayed radiation injury, and selected advanced diabetic wounds. Medicare coverage overlaps with several of these indications but applies its own medical-necessity and documentation requirements. (UHMS)

Referral Should Begin With the Surgical Diagnosis

The presence of a difficult wound is not, by itself, an indication for HBOT. The surgeon and hyperbaric physician must first determine why the tissue is failing.

Potential barriers include:

• Arterial obstruction

• Venous congestion

• Hematoma or seroma

• Excessive closure tension

• Flap pedicle compression or thrombosis

• Infection

• Retained necrotic tissue

• Radiation-associated vascular damage

• Repetitive pressure or shear

• Poorly controlled edema

• Inadequate offloading

• Malnutrition or metabolic dysfunction

HBOT can increase dissolved plasma oxygen, extend oxygen diffusion from functioning capillaries, reduce selected forms of edema, and support oxygen-dependent immune and reparative processes. It cannot correct a twisted pedicle, evacuate a hematoma, drain an abscess, reopen an occluded artery, stabilize a fracture, or remove necrotic tissue.

The central referral question is therefore:

Does the patient have hypoxic but viable tissue that may benefit from increased oxygen delivery after correctable surgical problems have been addressed?

Use Three Levels of Referral Urgency

Surgeons can organize HBOT referrals according to the rate at which tissue or organ viability is being lost.

Immediate emergency consultation is appropriate when treatment delay may result in major neurologic injury, limb loss, organ damage, or death. Examples include arterial gas embolism, severe carbon monoxide poisoning, decompression illness, and selected acute traumatic ischemias.

Urgent same-day consultation is appropriate for a compromised graft or flap, progressive traumatic tissue ischemia, necrotizing infection after emergency surgical evaluation, or threatened replanted tissue.

Planned consultation is generally appropriate for delayed radiation injury, chronic refractory osteomyelitis, selected advanced diabetic foot wounds, and preparation for complex surgery within a previously irradiated field.

Early consultation does not obligate the patient to undergo HBOT. It allows the hyperbaric team to determine whether an indication exists, whether additional source control is required, and whether the tissue remains salvageable.

Compromised Flaps Require Immediate Surgical Assessment

A threatened flap is one of the most time-sensitive surgical reasons to contact a hyperbaric center.

Warning findings may include:

• Increasing pallor

• Cyanosis or dark venous congestion

• Cool tissue

• Delayed capillary refill

• Progressive edema

• Loss or deterioration of a Doppler signal

• Epidermolysis

• Poor bleeding after pinprick

• Expanding tissue necrosis

The reconstructive surgeon must first evaluate for a surgically correctable cause. Arterial thrombosis, venous thrombosis, pedicle kinking, compression, hematoma, excessive tension, or technical anastomotic failure may require immediate return to the operating room.

HBOT should not be used as a substitute for flap exploration. It may be considered after mechanical and vascular causes have been corrected when tissue remains hypoxic but potentially viable.

UHMS states that HBOT is neither necessary nor recommended for normal, uncompromised grafts and flaps. Its role is as an adjunct for compromised tissue, and early initiation after compromise is recognized may improve the opportunity for salvage. (UHMS)

A strong referral communicates:

• Type and location of the flap

• Date and time of reconstruction

• Arterial and venous anatomy

• Onset and progression of compromise

• Doppler and clinical findings

• Operative revision already performed

• Presence of hematoma, infection, or venous congestion

• Current photographs

• Specific tissue the surgeon is attempting to preserve

The objective should be explicit, such as preserving complete flap coverage, reducing the area of debridement, avoiding implant exposure, or preventing the need for another free-tissue transfer.

Skin Graft Referral Should Be Selective

A skin graft depends on direct contact with a vascular recipient bed, early diffusion of oxygen and nutrients, and subsequent capillary connection. Hematoma, seroma, movement, infection, ischemia, and an inadequate wound bed can interfere with graft uptake.

Before referral, the surgeon should address:

• Fluid beneath the graft

• Loss of graft-to-bed contact

• Shear or displacement

• Constricting dressings

• Infection

• Inadequate debridement

• Recipient-bed perfusion

• Exposed structures that cannot support grafting

HBOT may be considered when a graft remains threatened by tissue hypoxia after these factors have been corrected. Medicare covers the preparation and preservation of compromised skin grafts, while specifically excluding HBOT as the primary management of ordinary wounds. (Centers for Medicare & Medicaid Services)

Routine prophylactic HBOT is not indicated for every split-thickness or full-thickness skin graft. Referral should describe an actual or highly credible threat to graft viability rather than the presence of a graft alone.

Replanted and Revascularized Tissue May Remain at Risk

Successful restoration of major arterial inflow does not immediately normalize the microcirculation. Replanted or revascularized tissue may remain threatened by edema, venous congestion, microvascular thrombosis, endothelial injury, and ischemia-reperfusion effects.

The vascular or reconstructive team must first confirm that the repair is technically intact. Loss of inflow, venous obstruction, compartment pressure, or compressive hematoma requires direct intervention.

HBOT may be considered when adequate macroscopic circulation has been restored but tissue remains at risk because of microvascular compromise. Medicare includes crush injury and the suturing of severed limbs among covered hyperbaric conditions when function, limb, or life is threatened. (Centers for Medicare & Medicaid Services)

Serial assessment should include:

• Arterial and venous Doppler findings

• Capillary refill

• Tissue temperature

• Motor and sensory function

• Compartment findings

• Edema

• Demarcation of necrosis

• Need for further operative revision

The treatment objective should be tissue preservation, not simply temporary improvement in color during oxygen exposure.

Acute Traumatic Ischemia Should Be Referred Early

Severe crush injury, open fracture, vascular disruption, and reperfusion can create a cycle of edema, microvascular compression, hypoxia, inflammation, and additional tissue loss.

HBOT may support viable tissue by increasing oxygen diffusion and reducing edema while definitive trauma care continues. It cannot replace:

• Hemorrhage control

• Vascular repair

• Fracture stabilization

• Fasciotomy

• Debridement

• Antibiotic treatment

• Management of rhabdomyolysis and systemic crush syndrome

The multicenter HOLLT randomized trial evaluated adjunctive HBOT after initial surgery for severe open lower-limb fractures. The combined primary outcome of necrosis or infection was numerically lower but not statistically significant. Tissue necrosis considered separately was lower in the HBOT group, and several later functional outcomes favored treatment. These findings support selective use in severe lower-limb trauma without justifying routine HBOT for every open fracture. (PubMed Central (PMC))

Referral is most appropriate when the surgeon believes there is a reversible zone of threatened tissue and preservation could change the level of debridement, reconstructive plan, limb function, or amputation risk.

The referral should include:

• Mechanism and time of injury
• Vascular findings
• Fracture classification
• Compartment findings
• Operative reports
• Debridement and fixation completed
• Revascularization status
• Current photographs
• Planned return to the operating room
• Critical-care and monitoring requirements

Compartment Syndrome Still Requires Fasciotomy

Acute compartment syndrome is a surgical emergency. HBOT must not delay decompression when clinical findings or pressure measurements support fasciotomy.

Hyperbaric consultation may become relevant after fasciotomy when:

• Muscle remains severely edematous and ischemic
• Viability is uncertain
• A high-energy crush mechanism threatens marginal tissue
• Reperfusion injury is progressing
• Additional tissue loss would materially affect limb function

An open but inadequately decompressed compartment still requires surgical reassessment. A chamber treatment should never be used as evidence that another operation is unnecessary.

Necrotizing Infection Requires Source Control First

Necrotizing fasciitis, Fournier gangrene, and clostridial myonecrosis require immediate operative evaluation, broad-spectrum antimicrobial therapy, resuscitation, and critical care.

IDSA recommends prompt surgical consultation for aggressive soft tissue infections associated with systemic toxicity or suspected necrotizing fasciitis or gas gangrene. It also recommends broad empiric antimicrobial therapy because these infections may be polymicrobial or monomicrobial. (IDSA)

HBOT may be considered after emergency source control has begun. Proposed benefits include support for leukocyte microbial killing, increased oxygenation of threatened tissue, edema reduction, and inhibition of selected anaerobic organisms or toxins.

The referral should not delay:

• Initial debridement
• Repeat debridement
• Antibiotic administration
• Hemodynamic resuscitation
• Airway support
• Drainage of an abscess
• Amputation when required for survival

A practical sequence is:

1. Recognize the surgical emergency.
2. Begin resuscitation and broad antimicrobial therapy.
3. Perform urgent exploration and debridement.
4. Stabilize the patient.
5. Contact the hyperbaric team if treatment can be integrated without delaying another operation.
6. Continue repeated surgical reassessment.

Transfer to another facility solely for HBOT may be harmful when the patient is unstable or immediate surgical care would be interrupted.

Chronic Osteomyelitis Should Be Refractory Before Referral

HBOT is not routine first-line treatment for acute osteomyelitis or every postoperative bone infection.

Referral is most appropriate for chronic refractory osteomyelitis that has persisted or recurred despite appropriate medical and surgical treatment. Medicare defines the covered indication as chronic refractory osteomyelitis unresponsive to conventional medical and surgical management. (Centers for Medicare & Medicaid Services)

Before referral, the surgical plan should address:

• Necrotic or sequestrated bone
• Abscesses
• Infected hardware
• Mechanical instability
• Sinus tracts
• Vascular insufficiency
• Culture-directed antimicrobial therapy
• Soft-tissue coverage

Useful referral records include:

• Operative reports
• Bone or deep-tissue cultures
• Pathology
• Imaging
• Antibiotic history
• Hardware status
• Vascular testing
• Previous reconstruction
• Evidence of persistence or recurrence

HBOT may improve oxygen-dependent immune activity and support bone and soft-tissue repair. It cannot sterilize an undebrided sequestrum or compensate for unstable fixation.

The hyperbaric physician, infectious disease specialist, and surgeon should agree on the treatment objective. This may include infection suppression before reconstruction, support of a limb-salvage procedure, or treatment after adequate debridement of recurrent disease.

Diabetic Foot Surgery Requires Comprehensive Standard Care

A diabetic foot wound should not be referred solely because it is chronic or postoperative.

The IWGDF conditionally recommends considering systemic HBOT for selected neuro-ischemic or ischemic diabetes-related foot ulcers when standard care has failed and the resources required for treatment are available. The certainty of evidence is considered low, making patient selection especially important. (IWGDF Guidelines)

Medicare generally requires:

• Type 1 or type 2 diabetes
• A lower-extremity wound related to diabetes
• Wagner grade III or higher
• Failure of at least 30 days of standard wound therapy
• Continued comprehensive wound care during HBOT
• Periodic documentation of measurable improvement

Covered standard care includes vascular assessment, revascularization when appropriate, debridement, offloading, glucose management, nutritional optimization, moist wound care, and treatment of infection. (Centers for Medicare & Medicaid Services)

Surgeons should obtain urgent consultation for severe diabetic foot infection, extensive gangrene, necrotizing infection, deep abscess, compartment syndrome, or severe ischemia. The 2023 IWGDF and IDSA infection guidance recommends early surgery with antibiotics for selected moderate and severe infections and urgent surgical consultation for these high-risk findings. (IDSA)

A hyperbaric referral should include:

• Wound location and duration
• Wagner classification
• Serial measurements
• Photographs
• Offloading method
• Vascular studies and interventions
• Debridement history
• Infection and osteomyelitis evaluation
• Culture results
• Glucose management
• Response during standard treatment

HBOT should not be used to postpone revascularization, drainage, debridement, or amputation when those interventions are required.

Radiation-Damaged Tissue Requires Diagnosis-Specific Planning

Previous radiation can produce progressive small-vessel injury, fibrosis, reduced tissue oxygenation, impaired cellular repair, and poor surgical healing. Symptoms may appear months or years after cancer treatment.

Surgeons may consider referral for:

• Soft tissue radionecrosis
• Osteoradionecrosis
• Chronic ulceration within a radiation field
• Nonhealing postoperative wounds in irradiated tissue
• Selected reconstructive procedures involving significantly damaged tissue
• Radiation cystitis or proctitis identified during surgical evaluation

Medicare covers soft tissue radionecrosis and osteoradionecrosis when HBOT is used as an adjunct to conventional treatment. UHMS also recognizes delayed radiation injury as an established hyperbaric indication. (Centers for Medicare & Medicaid Services)

The referral should include:

• Cancer diagnosis
• Radiation site
• Total dose and treatment dates
• Radiation plan or dose map when available
• Previous operations
• Current imaging
• Pathology
• Evidence excluding recurrent malignancy
• Extent of exposed or necrotic tissue
• Planned debridement or reconstruction

A new wound, mass, bleeding episode, or bone lesion within a previous cancer field should not automatically be attributed to radiation. Recurrence, infection, fistula, vascular disease, and a second malignancy may require investigation.

Routine Dental Prophylaxis After Radiation Is Not Automatically Indicated

Historical protocols frequently used HBOT around dental extraction or mandibular surgery after head and neck radiation. Current evidence supports a more selective approach.

The 2024 ISOO-MASCC-ASCO guideline concluded that evidence supporting routine HBOT for prevention or management of osteoradionecrosis of the jaw remains limited. The guideline emphasizes contemporary dental prevention, careful surgical technique, multidisciplinary assessment, and individualized management rather than automatic hyperbaric treatment for every post-radiation extraction. (ASCO Publications)

Referral may still be reasonable when:

• Established osteoradionecrosis is present
• A substantial volume of poorly vascularized irradiated bone is involved
• Previous surgery has failed
• Complex debridement and reconstruction are planned
• Soft tissue radionecrosis accompanies the bone injury
• The hyperbaric physician and head and neck team identify a specific treatment objective

The surgeon should provide radiation-dose information, dental imaging, the proposed operation, bone exposure history, infection findings, and evidence excluding recurrent disease.

Acute Thermal Burns Require Selective Referral

UHMS recognizes acute thermal burn injury as a hyperbaric indication, but HBOT is not routine treatment for every burn. Its proposed role is preservation of hypoxic but viable tissue within the zone surrounding irreversible injury.

Burn-center priorities remain:

• Airway management
• Fluid resuscitation
• Escharotomy or fasciotomy when indicated
• Early excision
• Grafting
• Infection management
• Nutritional support
• Rehabilitation

Referral may be considered for selected severe burns, threatened tissue, compromised grafts or flaps, or when the fire exposure has also caused carbon monoxide poisoning.

Coverage requires separate verification because Medicare nationally excludes thermal skin burns as a covered HBOT indication, even though a distinct complication such as carbon monoxide poisoning or a compromised graft may qualify independently. (Centers for Medicare & Medicaid Services)

Severe Perioperative Anemia Is an Exceptional Indication

In rare circumstances, a surgical patient may develop life-threatening anemia when transfusion is unavailable, incompatible, or declined.

HBOT can temporarily increase oxygen dissolved in plasma while the team:

• Stops hemorrhage
• Minimizes further blood loss
• Supports erythropoiesis
• Reduces unnecessary phlebotomy
• Optimizes cardiac output and ventilation
• Determines which blood products or alternatives are acceptable

HBOT does not restore red blood cell mass and should not delay operative hemostasis. This application requires a hospital-based hyperbaric facility capable of managing a critically ill patient under pressure.

Severe anemia is recognized by UHMS, but Medicare does not nationally cover exceptional blood-loss anemia under its current HBOT policy. (UHMS)

Do Not Refer Normal Postoperative Healing

HBOT is generally not indicated for:

• An uncomplicated surgical incision
• A healthy flap with normal perfusion
• A graft progressing normally
• Routine cosmetic surgery recovery
• Prevention of ordinary scarring
• Mild postoperative edema
• A superficial wound without optimized standard care
• Cellulitis without a recognized hyperbaric indication
• An undrained abscess
• An untreated arterial obstruction
• Routine rehabilitation after surgery

The fact that oxygen participates in healing does not mean that additional oxygen under pressure improves every postoperative outcome.

A referral should be based on a defined pathologic process, not a general desire to heal faster.

What to Do Before Contacting the Hyperbaric Center

For a chronic or nonemergency referral, surgeons should complete the diagnostic workup and initiate appropriate standard treatment.

Depending on the condition, this may include:

• Vascular assessment
• Imaging
• Deep cultures
• Pathology
• Debridement
• Antibiotic therapy
• Mechanical offloading
• Glucose optimization
• Nutritional assessment
• Smoking and nicotine counseling
• Evaluation for recurrent malignancy
• Revision of a compromised reconstruction

Emergency referrals are different. Consultation should occur in parallel with stabilization and surgery rather than after every diagnostic test has been completed.

Information to Include in the Referral

A complete referral allows the hyperbaric team to determine urgency, eligibility, and treatment safety without unnecessary delay.

Include:

• Specific diagnosis
• Clinical objective for HBOT
• Date and mechanism of injury or operation
• Symptom and wound timeline
• Operative reports
• Current photographs
• Imaging
• Pathology and cultures
• Vascular studies
• Radiation records
• Antibiotic history
• Standard care already completed
• Planned future operations
• Current medications
• Pulmonary and seizure history
• Implanted devices
• Need for ventilation, infusions, or invasive monitoring
• Insurance and authorization information when relevant

For a flap, graft, replanted part, or traumatic ischemia, direct surgeon-to-hyperbaric physician communication is preferable to a routine electronic referral.

Describe the Intended Endpoint

HBOT should begin with a measurable objective.

Possible endpoints include:

• Preservation of a graft or flap
• Reduction in the area requiring debridement
• Successful coverage of exposed bone or hardware
• Control of chronic radiation-related tissue breakdown
• Progress toward closure of a qualifying diabetic wound
• Improvement after treatment of refractory osteomyelitis
• Preservation of limb function
• Stabilization of threatened traumatic tissue

The treatment course should be reassessed when:

• Tissue necrosis continues to progress
• A new surgical problem appears
• No objective improvement is occurring
• Another operation becomes necessary
• The clinical objective has been achieved
• The patient can no longer be treated safely

A predetermined number of chamber sessions should not replace surgical and hyperbaric reassessment.

Prepare the Patient for Hyperbaric Safety Screening

The hyperbaric physician will make the final safety determination, but the surgeon should identify important concerns before transfer.

These may include:

• Known or suspected pneumothorax
• Significant chest trauma
• Pulmonary air trapping
• Mechanical ventilation
• Continuous infusions
• Implanted electronic devices
• External fixation
• Drains and negative-pressure systems
• Recent ear or sinus surgery
• Seizure history
• Fever
• Glucose instability
• Pregnancy
• Claustrophobia

Dressings, topical products, warming systems, batteries, electronics, and implanted devices must be reviewed for compatibility with the specific chamber.

The FDA advises hyperbaric facilities to follow the manufacturer’s instructions, monitor patients continuously, maintain trained staff, use appropriate grounding, perform required maintenance, and enforce strict fire-prevention controls. (U.S. Food and Drug Administration)

Refer to a Center With the Required Capability

Not every hyperbaric center can treat every surgical patient.

A stable outpatient with delayed radiation injury may be appropriate for a monoplace wound-center program. An intubated trauma patient, unstable necrotizing infection, or patient receiving vasoactive infusions requires a hospital program with appropriate chamber access, critical-care equipment, and trained personnel.

Before transfer, confirm:

• The center treats the specific indication.
• A qualified hyperbaric physician has accepted the patient.
• The facility can manage the patient’s acuity.
• Chamber-compatible equipment is available.
• Required surgical and critical-care support will remain accessible.
• Transfer will not delay a more urgent intervention.

The most sophisticated chamber cannot compensate for a facility that lacks appropriate staffing, emergency capability, or multidisciplinary support.

Coordinate Chamber Treatments With Surgical Care

Hyperbaric treatment should be integrated around the operative plan.

For time-sensitive conditions, the surgeon and hyperbaric physician should agree on:

• Timing of the next operation
• Whether HBOT should occur before or after surgery
• Frequency of wound inspection
• Dressing and device compatibility
• Criteria for return to the operating room
• Reassessment of tissue viability
• Treatment discontinuation criteria

A scheduled HBOT session should be cancelled or postponed when the patient needs an urgent operation.

The hyperbaric team should also know when a wound must remain covered, when a flap cannot be compressed, when an extremity needs a particular position, and whether drains or external fixation require special handling.

Clinical Recognition and Coverage Are Separate Decisions

Surgeons should distinguish among:

• Recognition by a professional hyperbaric organization
• Medical appropriateness for an individual patient
• Medicare national coverage
• Commercial payer authorization
• Facility capability

A patient may have a clinically recognized indication that is not covered by a particular payer. Another patient may have a covered diagnosis but fail to meet severity, standard-care, or continued-treatment requirements.

The hyperbaric center should verify coverage and authorization. The referring surgeon supports that process by documenting the diagnosis, severity, previous treatment, operative findings, and clinical objective accurately.

The Best Referral Occurs While Tissue Is Still Salvageable

The potential benefit of HBOT decreases when tissue has become irreversibly necrotic or when a correctable surgical problem remains untreated.

Surgeons should contact the hyperbaric team early when:

• A flap begins showing signs of compromise
• Replanted tissue remains ischemic after repair
• A crush injury has a threatened zone of viable tissue
• Radiation damage is complicating an operative plan
• Osteomyelitis is becoming refractory
• A qualifying diabetic wound fails despite comprehensive care

Early consultation allows the surgeon and hyperbaric physician to determine whether HBOT can change the reconstructive, functional, or limb-salvage outcome.

The chamber is most valuable when it supports decisive surgical care. It should never replace source control, vascular correction, debridement, fixation, reconstruction, or careful postoperative surveillance.

A Practical Framework for Recognizing Time-Sensitive Indications, Optimizing Standard Care, and Requesting Hyperbaric Consultation

Hyperbaric oxygen therapy, commonly abbreviated as HBOT, is a specialized medical treatment rather than a general method for accelerating recovery. It is most appropriate when increased oxygen delivery, pressure-mediated bubble reduction, edema control, antimicrobial support, or vascular remodeling can address a defined pathophysiologic problem.

Physicians should consider referral when a patient has a recognized hyperbaric indication, the tissue or organ remains potentially salvageable, and HBOT can be integrated without delaying definitive treatment. The referral should identify a specific objective, such as preserving a threatened flap, reducing neurologic injury after carbon monoxide poisoning, treating delayed radiation damage, or supporting an advanced hypoxic wound.

The Undersea and Hyperbaric Medical Society, or UHMS, maintains an indication framework that includes acute emergencies, tissue-salvage conditions, severe infections, selected chronic wounds, delayed radiation injury, and other defined disorders. Clinical recognition by UHMS is separate from Medicare or commercial insurance coverage, which may apply narrower eligibility and documentation requirements. (UHMS)

A Referral Should Address a Specific Clinical Problem

A useful hyperbaric referral should answer several questions:

• What is the precise diagnosis?
• Why is oxygen delivery or pressure therapy relevant?
• Is the condition emergent, urgent, or elective?
• What standard treatments have already been completed?
• What tissue, function, organ, or clinical outcome is being preserved?
• Is the patient stable enough for transport and chamber treatment?

A referral based only on a description such as “nonhealing wound” or “poor circulation” is rarely sufficient. The hyperbaric physician must determine whether the wound is failing because of hypoxia, ischemia, infection, radiation injury, inadequate source control, repeated pressure, or another problem.

HBOT should not replace surgery, revascularization, antimicrobial therapy, offloading, debridement, transfusion, or critical care. It is generally used to support those treatments when a recognized oxygen-responsive problem remains.

Refer Immediately for Air or Gas Embolism

Air or gas entering the arterial circulation can obstruct blood flow to the brain, spinal cord, heart, or other organs. It may occur during surgery, central venous catheter manipulation, interventional procedures, pulmonary barotrauma, diving, or mechanical ventilation.

Possible findings include:

• Sudden loss of consciousness
• Seizure
• Confusion
• Focal weakness
• Visual disturbance
• Chest pain
• Cardiovascular instability
• Stroke-like symptoms after a procedure

The patient should receive high-concentration oxygen and emergency stabilization while hyperbaric consultation is initiated. Recompression reduces gas-bubble volume, while oxygen accelerates inert-gas elimination and supports ischemic tissue.

A suspected arterial gas embolism should be treated as a time-sensitive emergency. Imaging should not delay consultation when the clinical history is convincing, because intravascular gas may no longer be visible by the time CT or MRI is completed. Air or gas embolism is recognized by UHMS and covered under the current Medicare national policy. (UHMS)

Refer Immediately for Decompression Illness

Decompression illness includes decompression sickness and arterial gas embolism associated with diving or another significant pressure exposure.

Symptoms may include:

• Deep joint or limb pain
• Numbness or tingling
• Weakness
• Difficulty walking
• Vertigo or hearing loss
• Bladder dysfunction
• Confusion
• Shortness of breath
• Cardiovascular collapse

The highest practical concentration of oxygen should be administered immediately. The patient should remain at rest, and unnecessary altitude exposure should be avoided during transport when possible.

A normal dive computer, symptom improvement with surface oxygen, or a delay in presentation does not exclude decompression sickness. Physicians should contact a diving-medicine or hyperbaric specialist rather than waiting for confirmatory imaging or laboratory testing. Recompression remains the definitive treatment for clinically significant decompression illness. (Centers for Medicare & Medicaid Services)

Refer Early for Significant Carbon Monoxide Poisoning

Every patient with suspected carbon monoxide poisoning should receive 100 percent oxygen promptly. Hyperbaric consultation is particularly appropriate when the patient has:

• Loss of consciousness
• Persistent confusion or neurologic impairment
• Seizure
• Cardiac ischemia or biomarker elevation
• Severe metabolic acidosis
• Significant exposure symptoms during pregnancy
• A high carboxyhemoglobin concentration
• A severe clinical presentation despite a lower measured concentration

The decision should not be made from the carboxyhemoglobin level alone. The measured value may fall substantially after the patient leaves the exposure and receives oxygen, while neurologic and cardiac injury may continue.

Patients exposed during a fire should also be evaluated for airway injury, pulmonary damage, trauma, and cyanide toxicity. HBOT must not delay airway management, antidotal therapy, cardiovascular stabilization, or burn care.

Carbon monoxide poisoning is a recognized hyperbaric indication and is covered by Medicare. The strongest referral pathway begins oxygen immediately and involves the hyperbaric center while the emergency evaluation is still underway. (Centers for Medicare & Medicaid Services)

Treat Sudden Monocular Vision Loss as an Emergency

Central retinal artery occlusion may produce sudden, painless loss of vision in one eye. The retinal tissue has limited tolerance for ischemia, making early recognition and consultation important.

A patient with suspected retinal artery occlusion needs urgent ophthalmologic and stroke evaluation. HBOT may provide oxygen to the inner retina through diffusion from the choroidal circulation while the arterial obstruction and systemic vascular risk are evaluated.

Referral should not be postponed until a routine outpatient ophthalmology appointment. The hyperbaric center should be contacted as soon as the diagnosis is suspected because the potential for visual recovery generally declines as retinal ischemia continues. UHMS includes central retinal artery occlusion within its arterial-insufficiency indications. (UHMS)

HBOT does not replace evaluation for embolic disease, giant cell arteritis, carotid disease, cardiac sources, or cerebral ischemia. The patient still requires an appropriate stroke and vascular workup.

Refer Urgently for Acute Traumatic Ischemia and Crush Injury

Severe trauma can create a cycle of edema, microvascular compression, tissue hypoxia, inflammation, and progressive necrosis. HBOT may support viable tissue in selected crush injuries, compartment syndromes, replantations, and other acute traumatic ischemias.

Referral may be appropriate when:

• A limb remains threatened after vascular repair
• Severe edema compromises marginal tissue
• A crush injury places muscle and skin at risk
• A replanted or revascularized body part remains ischemic
• Tissue remains compromised after fasciotomy
• A high-energy open fracture has extensive soft-tissue injury

HBOT must not delay hemorrhage control, revascularization, fracture stabilization, fasciotomy, debridement, or another required operation. A closed compartment that needs surgical decompression cannot be treated adequately with oxygen alone.

Medicare recognizes acute traumatic peripheral ischemia and crush injuries involving the suturing of severed limbs when function, limb, or life is threatened. (Centers for Medicare & Medicaid Services)

Refer Early for Compromised Grafts and Flaps

A healthy graft or flap does not require routine HBOT. Referral becomes appropriate when a reconstruction shows evidence of hypoxia, ischemia, or venous compromise and viable tissue may still be salvaged.

Warning findings include:

• Increasing pallor or cyanosis
• Cool tissue
• Delayed capillary refill
• Progressive edema
• Loss of a Doppler signal
• Epidermal separation
• Expanding necrosis
• Failure of a skin graft to establish uptake

The operating surgeon should evaluate the patient immediately. A hematoma, thrombosed anastomosis, twisted pedicle, constricting dressing, fluid collection, or mechanical disruption requires direct correction.

HBOT may then support tissue that remains compromised after remediable causes have been addressed. Referral should occur while the tissue remains potentially viable, not after the entire reconstruction has become irreversibly necrotic. Medicare covers preparation and preservation of compromised skin grafts, but not HBOT as the primary management of ordinary wounds. (Centers for Medicare & Medicaid Services)

Refer Urgently for Necrotizing and Clostridial Infections

Necrotizing soft tissue infections and clostridial myonecrosis require emergency surgery, broad antimicrobial therapy, resuscitation, and critical care.

Findings that should prompt immediate surgical evaluation include:

• Pain disproportionate to visible skin changes
• Rapidly progressive swelling or erythema
• Bullae or ecchymosis
• Crepitus
• Skin anesthesia
• Severe systemic toxicity
• Shock
• Gas within deep tissue

HBOT may be considered after urgent source control has begun. Potential benefits include increased oxygenation of threatened tissue, support for leukocyte microbial killing, reduction of edema, and inhibition of selected anaerobic organisms or toxin production.

A chamber treatment must never take priority over an indicated debridement. Transfer solely for HBOT may be inappropriate when it removes an unstable patient from immediate surgical care.

Gas gangrene and progressive necrotizing infections are included in the Medicare coverage framework, while UHMS also recognizes necrotizing soft tissue infection as a hyperbaric indication. (Centers for Medicare & Medicaid Services)

Consider Referral for Exceptional Severe Anemia

HBOT may function as a temporary bridge in exceptional life-threatening anemia when red blood cell transfusion cannot be performed because compatible blood is unavailable, transfusion is declined, or another extraordinary barrier exists.

The clinical concern is inadequate tissue oxygen delivery, which may present with:

• Myocardial ischemia
• Altered mental status
• Persistent lactic acidosis
• Hemodynamic instability
• Progressive organ dysfunction

HBOT increases dissolved plasma oxygen temporarily. It does not restore red blood cell mass, stop hemorrhage, or replace definitive hematologic treatment.

Referral should occur alongside hemorrhage control, iron replacement, erythropoietic support when appropriate, blood-conservation measures, and critical care. The receiving center must be capable of managing the patient’s full acuity under pressure.

Severe anemia is recognized within the UHMS indication framework, but Medicare’s national policy does not currently cover exceptional blood-loss anemia. (UHMS)

Refer Selected Patients With Delayed Radiation Injury

Radiation can produce progressive vascular injury, fibrosis, chronic tissue hypoxia, ulceration, bleeding, and impaired healing months or years after cancer treatment.

Referral may be appropriate for suspected:

• Radiation cystitis
• Radiation proctitis
• Soft tissue radionecrosis
• Osteoradionecrosis
• Nonhealing wounds within a radiation field
• Reconstructive failure involving irradiated tissue

The referring physician should provide radiation records when available, including the treatment site, dose, dates, and relevant operative history.

Other causes must still be evaluated. Hematuria requires appropriate urologic assessment, rectal bleeding requires gastrointestinal or colorectal evaluation, and a new wound in a previous cancer field may require biopsy or imaging to exclude recurrent malignancy.

Medicare covers soft tissue radionecrosis and osteoradionecrosis when HBOT is provided as an adjunct to conventional treatment. (Centers for Medicare & Medicaid Services)

Referral is most useful when the diagnosis has been characterized and the treatment objective is clear. HBOT may be used to reduce bleeding, improve tissue health, support healing, or prepare selected patients for debridement and reconstruction.

Refer Chronic Osteomyelitis After Standard Treatment Has Failed

HBOT may be considered for chronic refractory osteomyelitis, not for every case of bone infection.

A useful referral should document:

• The affected bone and duration of infection
• Imaging findings
• Operative and pathology reports
• Deep tissue or bone cultures
• Antimicrobial regimens
• Debridement history
• Hardware status
• Vascular assessment
• Evidence of persistence or recurrence

Necrotic bone, abscesses, unstable hardware, and biofilm require appropriate surgical and infectious disease management. HBOT may support oxygen-dependent immune function, bone repair, and antimicrobial effectiveness in selected hypoxic tissue, but it does not provide source control.

Medicare covers chronic refractory osteomyelitis that has not responded to conventional medical and surgical management. (Centers for Medicare & Medicaid Services)

Referral before adequate treatment has been attempted may be premature. Waiting until infection has produced extensive destruction may also reduce the likelihood of successful reconstruction. Early discussion with the hyperbaric team can help determine whether the patient is approaching a refractory course.

Refer Selected Advanced Diabetic Foot Ulcers

A diabetic foot ulcer should not be referred for HBOT solely because it has been present for several weeks.

The wound first requires comprehensive evaluation and management, including:

• Vascular assessment and revascularization when feasible
• Pressure offloading
• Debridement
• Infection treatment
• Glucose management
• Nutritional assessment
• Moisture-balanced wound care
• Appropriate surgical consultation

The 2023 International Working Group on the Diabetic Foot guideline conditionally recommends considering systemic HBOT for neuro-ischemic or ischemic diabetes-related foot ulcers when standard care alone has failed and the resources needed to provide treatment are available. The guideline rates the certainty of evidence as low and emphasizes appropriate patient selection.

For Medicare coverage, the patient must generally have type 1 or type 2 diabetes, a lower-extremity wound related to diabetes, a Wagner grade III or higher wound, and no measurable healing after at least 30 days of standard wound therapy. HBOT must continue alongside comprehensive wound care, and measurable progress must be reassessed during treatment. (Centers for Medicare & Medicaid Services)

Referral documentation should include wound measurements, depth, Wagner classification, vascular findings, offloading method, debridement history, infection management, imaging, glucose control, and the response to standard care.

A superficial ulcer that remains open because the patient continues walking on it without effective offloading is not primarily an oxygen-delivery problem.

Refer Promptly for Sudden Sensorineural Hearing Loss

Sudden sensorineural hearing loss is an urgent otologic condition, often presenting as rapid unilateral hearing loss with tinnitus, ear fullness, or vertigo.

The American Academy of Otolaryngology–Head and Neck Surgery guideline states that clinicians may offer or refer for HBOT combined with steroid therapy within two weeks of symptom onset. HBOT combined with steroids may also be offered as salvage treatment within one month when hearing recovery is incomplete. (AAO-HNS)

The patient should first receive prompt evaluation to distinguish sensorineural loss from conductive hearing loss and identify alternative causes. Audiometry and otolaryngology involvement are important, but delays in routine scheduling can reduce the available treatment window.

HBOT should be presented as an option within a shared decision-making process rather than a guaranteed method of restoring hearing. The evidence remains imperfect, and treatment requires repeated chamber sessions in addition to steroid management.

Consider Referral for Selected Intracranial Abscesses

HBOT may be considered in selected intracranial abscesses, particularly when infection is multiple, deep, recurrent, associated with immune compromise, or inadequately responsive to surgery and antimicrobial therapy.

This is not a routine first-line treatment. Neurosurgical drainage, organism identification, antimicrobial therapy, imaging, and management of intracranial pressure remain essential.

Referral should involve direct communication among neurosurgery, infectious disease, critical care, and hyperbaric medicine. The chamber facility must be capable of managing neurologic deterioration, seizures, mechanical ventilation, and invasive monitoring when those needs are present.

Intracranial abscess is recognized within the UHMS hyperbaric indication framework but is not included among the nationally covered Medicare conditions in NCD 20.29. (UHMS)

Do Not Delay Definitive Care While Seeking HBOT

For emergency conditions, HBOT consultation should occur in parallel with stabilization and definitive treatment.

Examples include:

• Surgery before or between treatments for necrotizing infection
• Fasciotomy for confirmed compartment syndrome
• Vascular repair for traumatic arterial disruption
• Revision of a thrombosed flap pedicle
• Airway stabilization in smoke inhalation
• Antimicrobial therapy and drainage for infection
• Hemorrhage control in severe anemia

UHMS guidance on emergent and urgent services emphasizes prompt treatment at the closest appropriate facility for stable patients while directing unstable or critically ill patients to a center capable of providing the required level of care. (UHMS)

The chamber should support the treatment plan. It should never become an obstacle between the patient and a more urgent operation or resuscitative intervention.

Information the Hyperbaric Center Needs

A high-quality referral should include the information required to determine indication, urgency, safety, and treatment feasibility.

Useful records may include:

• Diagnosis and symptom timeline
• Treatment objective
• Current clinical stability
• Operative reports
• Imaging
• Culture and pathology results
• Radiation records
• Wound measurements and photographs
• Vascular studies
• Audiograms
• Carboxyhemoglobin, blood gas, lactate, ECG, and cardiac biomarkers
• Dive profile and neurologic findings
• Current medications
• Implanted and external medical devices
• Pulmonary history
• Prior chamber exposure

For an urgent case, physicians should call the hyperbaric service directly rather than relying solely on an electronic referral that may not be reviewed immediately.

The referring team should describe why the condition is urgent, which interventions have been completed, and what level of monitoring the patient currently requires.

Safety Screening Should Begin Before Transfer

The hyperbaric physician performs the definitive treatment assessment, but the referring clinician can identify issues that may affect chamber safety.

Relevant considerations include:

• Known or suspected pneumothorax
• Pulmonary air trapping or significant bullous disease
• Recent thoracic procedures
• Uncontrolled seizure activity
• Fever
• Glucose instability
• Difficulty equalizing ear pressure
• Severe claustrophobia
• Hemodynamic instability
• Implanted medical devices
• Mechanical ventilation
• Continuous infusions
• Pregnancy
• Medications that may affect oxygen tolerance

Significant pulmonary air trapping and a history of spontaneous pneumothorax require careful risk-benefit analysis. A pneumothorax may require tube thoracostomy before recompression, particularly when pressure changes could cause expansion during decompression. (UHMS)

A potential safety concern does not always eliminate treatment, especially during a life-threatening emergency. It determines the preparation, chamber type, equipment, monitoring, and clinical team required.

Choose a Qualified Medical Hyperbaric Facility

Patients should be referred to a facility that can safely manage the diagnosis and level of acuity.

A stable outpatient wound program may not be equipped to accept an intubated patient with arterial gas embolism or necrotizing infection. A critical-care hyperbaric center may require direct physician-to-physician communication before transfer.

The FDA states that HBOT chambers are Class II medical devices and advises facilities to follow manufacturer instructions, maintain staff training, monitor patients throughout treatment, complete recommended maintenance, and enforce strict fire-prevention controls. FDA-cleared devices can be identified under product code CBF. (U.S. Food and Drug Administration)

Important facility questions include:

• Is the center medically supervised?
• Does it treat the specific indication?
• Can it accept emergency or inpatient cases?
• Can it manage mechanical ventilation and infusions?
• Is a surgeon, intensivist, or other specialist available when needed?
• Does it have established emergency and fire-safety systems?
• Is it accredited or actively aligned with recognized hyperbaric standards?

A low-pressure wellness chamber should not be assumed to provide the oxygen dose, equipment, supervision, or emergency capability required for clinical HBOT.

Know When HBOT Referral Is Unlikely to Help

Referral is generally not appropriate merely because a condition involves inflammation, fatigue, a chronic wound, or slow recovery.

Examples that usually require another primary approach include:

• A normally healing surgical incision
• An uncomplicated skin graft or flap
• A superficial diabetic ulcer without optimized offloading
• Cellulitis without a recognized hyperbaric indication
• Untreated arterial obstruction
• An undrained abscess
• Routine chronic anemia
• General wellness or athletic recovery
• Cosmetic scar improvement
• Uncomplicated postoperative recovery
• Neurologic conditions offered outside established care or a structured research protocol

The absence of an established indication does not mean that oxygen has no biologic effect. It means that sufficient clinical evidence, treatment standardization, or patient-selection guidance may not exist to support routine referral.

Physicians can still contact a qualified hyperbaric specialist when the diagnosis is uncertain. Consultation does not obligate the patient to undergo treatment.

Clinical Appropriateness and Insurance Coverage Must Be Evaluated Separately

UHMS indication recognition, FDA device clearance, Medicare coverage, and commercial payer authorization are different determinations.

A condition may be recognized clinically but not nationally covered by Medicare. Acute thermal burns and exceptional blood-loss anemia are examples of conditions that may be recognized within hyperbaric medicine but remain nationally noncovered under the current Medicare policy. Conversely, Medicare coverage for a listed diagnosis still requires documentation that the patient satisfies the applicable clinical criteria. (Centers for Medicare & Medicaid Services)

The hyperbaric center should verify coverage, authorization, and documentation requirements. The referring physician can support this process by providing complete records rather than relying on a diagnosis code alone.

For emergency conditions, financial authorization should not delay stabilization or time-sensitive specialist consultation.

The Best Time to Refer Is Before Salvage Becomes Impossible

HBOT is often most valuable in tissue that is threatened but still viable. Referral after a flap is completely necrotic, a retina has sustained prolonged irreversible ischemia, or a wound has progressed without appropriate vascular and surgical care may come too late to change the outcome.

Early referral does not always mean immediate treatment. It allows the hyperbaric physician to determine whether HBOT is indicated, what prerequisites remain, and when treatment would have the greatest biologic relevance.

Physicians should refer when there is a recognized diagnosis, a defined therapeutic objective, and a reasonable expectation that increased oxygen delivery or recompression can influence the patient’s outcome. For emergencies, consultation should occur immediately. For chronic conditions, referral should follow careful diagnostic workup and optimization of standard care.

The most effective referrals connect HBOT to a coordinated treatment plan rather than treating the chamber as an isolated solution.

Why Health Systems Are Expanding HBOT Services and What Determines Whether a Program Becomes Clinically and Financially Sustainable 

Hospital interest in hyperbaric oxygen therapy, commonly abbreviated as HBOT, has grown alongside the development of advanced wound care, limb-preservation services, cancer survivorship programs, reconstructive surgery, and regional emergency referral networks.

The expansion is not driven by one clinical condition or one business model. Some hospitals operate several monoplace chambers within an outpatient wound center. Academic and tertiary hospitals may maintain multiplace chambers capable of treating critically ill patients, diving emergencies, arterial gas embolism, severe carbon monoxide poisoning, or complex surgical complications.

No complete national census describes how many hospital-based hyperbaric programs are currently operating, opening, closing, or changing ownership. The Undersea and Hyperbaric Medical Society, or UHMS, reports that its facility accreditation program has surveyed and accredited more than 267 facilities over nearly 20 years. This cumulative figure includes different facility types and should not be interpreted as the current number of hospital programs. It does, however, demonstrate the development of a substantial clinical infrastructure requiring specialty-specific standards. (UHMS)

The more important question for hospital leaders is not whether hyperbaric medicine is expanding. It is whether a proposed program can meet a defined regional need while maintaining appropriate patient selection, qualified staffing, engineering controls, fire safety, documentation, and measurable clinical outcomes.

Chronic Wounds Are a Major Driver of Program Development

Advanced wound care is one of the most common entry points for hospital HBOT programs. Diabetes, peripheral arterial disease, neuropathy, infection, pressure, renal disease, and impaired mobility can combine to produce wounds that require prolonged multidisciplinary treatment.

Diabetes-related lower-extremity complications remain a substantial health-system burden. The CDC reports that hospitalizations involving diabetes-related amputations doubled between 2009 and 2019. It also emphasizes that vascular assessment, revascularization when appropriate, foot surveillance, and early wound treatment are important components of amputation prevention. (CDC)

This burden has encouraged hospitals to build integrated limb-preservation programs involving:

• Vascular surgery
• Podiatry
• Orthopedic surgery
• Infectious disease
• Endocrinology
• Wound care
• Rehabilitation
• Hyperbaric medicine

HBOT may be useful for selected advanced diabetic lower-extremity wounds, but most diabetic ulcers do not automatically qualify for treatment. Medicare coverage generally requires a diabetes-related lower-extremity wound classified as Wagner grade III or higher, failure of at least 30 days of standard wound therapy, and continued comprehensive wound care during HBOT. (Centers for Medicare & Medicaid Services)

A hospital that estimates demand by counting every patient with diabetes or every chronic wound will overstate the addressable population. Sustainable growth depends on identifying patients who meet clinical and payer criteria after vascular, infectious, mechanical, and metabolic barriers have been addressed.

Cancer Survivorship Is Increasing Demand for Late-Effect Management

As more people live for years after cancer treatment, hospitals are managing a larger population with delayed treatment effects. The National Cancer Institute estimated that the United States had approximately 18.6 million cancer survivors as of May 2025. (Cancer Control)

Radiation therapy can produce late complications months or years after treatment. These may involve the bladder, rectum, jaw, skin, soft tissue, chest wall, or other structures within the treatment field. NCI guidance recognizes that radiation can damage nearby healthy tissue and that late effects depend on the treated region, combined therapies, genetics, smoking, and other patient factors. (Cancer.gov)

Hospitals with active radiation oncology, urology, colorectal surgery, head and neck surgery, dental oncology, and reconstructive services may therefore encounter patients with:

• Radiation cystitis
• Radiation proctitis
• Soft tissue radionecrosis
• Osteoradionecrosis
• Nonhealing wounds in irradiated tissue
• Compromised reconstructive procedures

HBOT is recognized for delayed radiation injury in selected patients and is covered by Medicare for soft tissue radionecrosis and osteoradionecrosis when used alongside conventional treatment. (Centers for Medicare & Medicaid Services)

This referral pathway can be particularly valuable to hospitals because the hyperbaric program becomes part of long-term cancer survivorship rather than an isolated wound service. Patients may require coordinated evaluation by oncology, urology, gastroenterology, oral surgery, plastic surgery, and other specialists before HBOT is prescribed.

Hospitals Can Integrate HBOT With Existing Specialty Services

A hospital has several operational advantages when hyperbaric medicine is integrated with established clinical departments.

A patient with a complex diabetic foot wound may need vascular imaging, revascularization, debridement, antimicrobial therapy, offloading, glucose management, and rehabilitation. A patient with a compromised free flap may require immediate evaluation by the reconstructive surgeon. A patient with necrotizing infection may need repeated operations and intensive care.

Hospital integration can provide direct access to:

• Operating rooms
• Emergency medicine
• Critical care
• Diagnostic imaging
• Laboratory services
• Vascular intervention
• Infectious disease consultation
• Pharmacy
• Respiratory therapy
• Rehabilitation
• Blood bank and transfusion services

This infrastructure is especially important because HBOT is an adjunctive treatment. CMS states that covered hyperbaric therapy should not replace successful standard therapeutic measures. (Centers for Medicare & Medicaid Services)

A chamber located within or closely connected to a hospital may reduce fragmentation, but physical proximity alone does not create clinical integration. Referral pathways, communication responsibilities, emergency procedures, and continued ownership of the underlying disease must be defined formally.

Outpatient Wound Centers Have Become a Common Growth Model

Many hospital hyperbaric programs are developed within outpatient wound centers. This model may use one or more monoplace chambers to treat stable patients during regular weekday hours.

The model can be attractive because it combines:

• Recurring outpatient visits
• Existing wound-care referrals
• Shared nursing and administrative infrastructure
• Hospital outpatient reimbursement
• Coordination with vascular and surgical services
• Predictable treatment scheduling

Medicare’s current claims-processing guidance identifies G0277 as the hospital outpatient facility code for full-body chamber treatment per 30-minute interval. The guidance states that G0277 is not available for use outside a hospital outpatient department in the same manner. Physician attendance and supervision are generally reported separately with CPT 99183. (Centers for Medicare & Medicaid Services)

This reimbursement structure has contributed to the hospital outpatient model, but it does not guarantee profitability. Revenue depends on completed treatments, payer contracts, medical necessity, documentation, denials, staffing expense, chamber utilization, and the number of patients who complete their prescribed courses.

A hospital should not open a program solely because reimbursement exists. It should establish that enough clinically appropriate patients can access and complete treatment without relying on unsupported indications or excessive utilization.

Tertiary Hospitals May Develop Critical-Care Capability

A smaller group of hospital programs is designed to treat emergency and high-acuity indications.

These may include:

• Arterial gas embolism
• Decompression sickness
• Severe carbon monoxide poisoning
• Acute traumatic ischemia
• Necrotizing soft tissue infection
• Compromised replantation or reconstruction
• Exceptional severe anemia when transfusion is impossible

Such capability generally requires more than an outpatient monoplace service. The hospital may need a multiplace chamber, inside attendants, chamber-compatible ventilators, infusion systems, advanced monitoring, respiratory therapy, critical-care nursing, and immediate physician availability.

The program must also coordinate with:

• Emergency medical services
• Regional poison centers
• Diving medicine resources
• Trauma surgery
• Intensive care
• Anesthesiology
• Neurology
• Cardiothoracic and vascular services

Emergency-capable programs may not produce the same predictable treatment volume as outpatient wound programs. Their value may instead involve regional preparedness, patient retention, support for complex hospital services, and access to time-sensitive treatment.

Hospitals should evaluate this strategic role separately from the routine outpatient business case. A program cannot claim 24-hour emergency capability unless a complete chamber team can be mobilized reliably outside normal operating hours.

Regional Hub-and-Spoke Networks May Support Growth

Not every hospital needs its own hyperbaric chamber. In some regions, a hub-and-spoke model may provide better coverage.

Under this model:

• Community hospitals identify possible indications.
• A regional hyperbaric physician provides early consultation.
• Emergency stabilization begins locally.
• Transfer criteria are defined in advance.
• A tertiary center accepts complex or critical patients.
• Stable patients may receive follow-up treatment closer to home.

This approach can be especially useful for carbon monoxide poisoning, diving emergencies, gas embolism, acute traumatic ischemia, and complex radiation injuries.

A regional model requires more than a referral phone number. It should establish:

• Medical acceptance criteria
• Transfer pathways
• Transport altitude considerations
• Required records and imaging
• Stabilization expectations
• After-hours contacts
• Return-transfer and follow-up plans

Hospitals should also map the actual travel burden for outpatient patients. A prescription for 30 or 40 weekday treatments may be clinically reasonable but practically impossible when the patient lives several hours away and lacks reliable transportation.

Accreditation Is Becoming More Important as Programs Expand

Growth increases the need for standardization. Hyperbaric medicine combines medical treatment, pressure-vessel operation, oxygen fire risk, environmental control, and restricted access to patients under pressure.

UHMS accreditation evaluates the facility as a complete clinical system. It reviews staffing, training, equipment, maintenance, safety practices, documentation, patient care, and quality improvement. UHMS states that its accreditation program is recognized by The Joint Commission as a complementary accrediting organization under a cooperative initiative. (UHMS)

Accreditation may help a hospital:

• Structure program development
• Validate safety systems
• Standardize staff competencies
• Strengthen referral confidence
• Prepare for external review
• Demonstrate organizational commitment
• Identify gaps before an adverse event occurs

Accreditation does not replace state licensure, hospital accreditation, FDA requirements, NFPA compliance, ASME pressure-vessel standards, or payer rules. It adds specialty-specific scrutiny to those broader obligations.

A growing program should incorporate accreditation expectations during planning rather than trying to reconstruct policies, staffing files, and maintenance records shortly before a survey.

Fire Safety Is Central to Responsible Expansion

Hyperbaric chambers expose patients and equipment to increased pressure and, depending on chamber design, highly concentrated oxygen. These conditions require strict ignition prevention, material control, grounding, maintenance, and emergency preparation.

In August 2025, the FDA issued a safety communication after receiving reports of fires involving HBOT devices that resulted in serious injuries and deaths. The agency instructed facilities to follow manufacturer requirements, maintain fire-prevention measures, use proper grounding, train staff, supervise patients throughout treatment, follow maintenance schedules, and control electrical, static-producing, and incompatible items. (U.S. Food and Drug Administration)

The FDA also confirmed that HBOT devices are Class II medical devices cleared through the 510(k) process and can be identified under product code CBF. (U.S. Food and Drug Administration)

Program growth should therefore include proportional investment in:

• Hyperbaric safety leadership
• Product and dressing review
• Preventive maintenance
• Fire drills
• Staff competency validation
• Environmental monitoring
• Chamber-approved clothing
• Equipment compatibility
• Adverse-event reporting

Adding another chamber without adding the staff, maintenance capacity, and safety oversight required to operate it can increase risk rather than access.

Workforce Availability Can Limit Expansion

Hyperbaric medicine requires personnel with specialized clinical and technical competencies. A hospital may have sufficient referral volume and capital but still be unable to operate safely because qualified staff are unavailable.

The team may include:

• Hyperbaric medical director
• Credentialed attending physicians
• Advanced practice providers where permitted
• Registered nurses
• Hyperbaric technologists
• Chamber operators
• Inside and outside attendants
• Respiratory therapists
• Hyperbaric safety director
• Program manager
• Revenue-cycle personnel

The challenge is not only recruitment. Staff must complete hyperbaric education, chamber-specific orientation, supervised clinical experience, emergency simulation, and continued competency validation.

Workforce fragility can be significant. A program dependent on one physician, one technologist, or one safety specialist may close temporarily when that individual is ill, resigns, retires, or cannot provide after-hours coverage.

Hospitals considering expansion should evaluate staffing redundancy before purchasing additional equipment. The theoretical chamber capacity has little value when the organization cannot staff every active treatment safely.

Technology Has Made Some Programs More Operationally Feasible

Modern chambers may include digital pressure controls, treatment-profile displays, integrated environmental monitoring, improved communications, and more complete treatment-data capture.

These advances can support:

• Consistent compression and decompression
• Timed oxygen periods and air breaks
• Environmental alarms
• Treatment verification
• Electronic documentation
• Preventive maintenance tracking
• More effective patient observation

Technology has also improved the ability of selected hospital programs to treat ventilated or critically ill patients. Chamber-compatible monitoring, ventilators, infusion systems, and communication equipment can allow necessary organ support to continue under pressure.

These advances do not reduce the need for trained personnel. Automated chamber controls cannot perform a neurologic examination, recognize subtle confusion, manage a seizure, correct a failing airway, or determine whether a treatment should be stopped.

Expansion based on technology should therefore focus on improved safety and clinical capability rather than reduced staffing.

Reimbursement Supports Growth but Also Creates Compliance Risk

Hospital outpatient reimbursement can make a hyperbaric program financially viable, particularly when chambers maintain appropriate utilization. The economic model remains sensitive to reimbursement changes, payer mix, staffing costs, treatment completion, denials, and capital expense.

A 2024 analysis of Medicare payment trends reported that the estimated total Medicare cost of a 40-treatment course decreased from approximately $27,562 in 2013 to $23,834 in 2022. The estimated 2022 cost per session was approximately $596. These figures represent national Medicare payment analysis, not the expected revenue or contribution margin for a specific hospital. (PubMed)

Hospitals must build projections from their own:

• Contractual allowed amounts
• Payer mix
• Collection rates
• Authorization requirements
• Labor costs
• Oxygen and supply expense
• Maintenance contracts
• Cancellation rates
• Chamber capacity
• Capital and construction costs

A high charge per treatment does not establish a high margin. The program must account for preparation time, cleaning, safety checks, compression, decompression, documentation, maintenance downtime, and patients who discontinue before completing the planned course.

Utilization Must Be Clinically Defensible

Hyperbaric services have received sustained federal scrutiny because of concerns about medical necessity, supervision, coding, and excessive treatment.

A CMS prior-authorization demonstration was implemented in three states selected for high HBOT utilization and claims error rates. Approximately 113 providers were affected. The program was designed to review documentation before nonemergent treatment for selected conditions and reduce payment for services that did not satisfy coding, coverage, and medical-necessity requirements.

Federal audits and enforcement actions have also identified improper HBOT payments. One Office of Inspector General audit found that only 5 of 120 sampled outpatient claims reviewed through a Medicare contractor complied with requirements, with an estimated $39.3 million in potential overpayments associated with nonsampled claims. (Health OIG)

Other federal settlements have involved allegations concerning medically unnecessary treatments, excessive units, inadequate supervision, and failure to meet provider-based billing requirements. (Health OIG)

These findings should not be interpreted as evidence that hospital HBOT is inherently improper. They show that growth without strong utilization controls can create repayment, penalty, and reputational risk.

A responsible program should verify:

• The qualifying diagnosis
• Required standard therapy
• Severity and staging criteria
• Medical necessity
• Treatment prescription
• Physician supervision
• Objective clinical response
• Continued-treatment justification
• Correct professional and facility coding

Chamber availability must never become the reason a patient continues treatment.

Outsourced Management Can Accelerate Growth but Requires Oversight

Some hospitals develop hyperbaric programs internally. Others contract with companies that provide program development, staffing assistance, referral support, operational systems, or wound-center management.

Contracted models may offer:

• Startup expertise
• Recruitment support
• Standardized policies
• Revenue-cycle processes
• Data dashboards
• Marketing and referral development
• Accreditation preparation

They can also create governance challenges when the hospital assumes that clinical and compliance responsibilities have been transferred to the contractor.

The hospital remains responsible for patient care delivered under its name, facility billing, medical-staff privileging, life safety, equipment maintenance, and compliance with provider-based requirements. Contract language should define authority, reporting, clinical independence, quality review, and responsibility for correcting deficiencies.

Financial incentives should not reward unnecessary treatment volume. The medical director must retain authority to decline a referral, modify a course, or discontinue HBOT when further treatment is not clinically justified.

Growth Should Be Measured Through More Than Treatment Volume

Chamber utilization is important, but it is not an adequate measure of program quality.

A mature hospital program should track:

• Qualified referrals
• Referral-to-consult conversion
• Authorization approval
• Treatment completion
• Clinical outcome by diagnosis
• Wound closure
• Amputation
• Radiation-related symptom improvement
• Graft or flap salvage
• Treatment complications
• Emergency decompression
• Barotrauma
• Glucose-related interruptions
• Documentation deficiencies
• Denials and recoupments
• Patient travel and treatment burden

Outcomes should be stratified by diagnosis. Combining diabetic foot wounds, radiation cystitis, carbon monoxide poisoning, and compromised flaps into one overall success rate provides little useful information.

The hospital should also examine whether HBOT changes meaningful downstream outcomes. These may include fewer operations, reduced transfusion requirements, preservation of reconstruction, shorter wound-care duration, improved function, or reduced hospitalization.

The Business Case Should Include Downstream Service-Line Value

HBOT may strengthen several hospital service lines even when direct chamber margin is modest.

Potential downstream relationships include:

• Limb preservation
• Vascular surgery
• Podiatry
• Orthopedics
• Infectious disease
• Radiation oncology survivorship
• Urology
• Colorectal surgery
• Plastic surgery
• Trauma
• Rehabilitation

This value should be calculated carefully. A hospital should not attribute every subsequent laboratory test, admission, or surgical procedure to the hyperbaric program.

A useful financial framework separates:

1. Direct HBOT revenue and expense
2. Attributable downstream contribution
3. Documented cost avoidance
4. Strategic regional value

This prevents double counting and allows leadership to see whether the program is operationally self-sustaining.

Some Hospitals Should Expand While Others Should Build Referral Partnerships

Not every organization with a wound center needs a chamber.

Expansion may be reasonable when the hospital has:

• Documented eligible referral volume
• Meaningful patient outmigration
• Established vascular and surgical support
• Radiation survivorship demand
• Qualified medical leadership
• Adequate staffing redundancy
• Favorable payer contracts
• Appropriate construction space
• Long-term maintenance resources
• Commitment to accreditation and quality measurement

A referral partnership may be more appropriate when:

• Eligible volume is low
• Another qualified center is nearby
• Staffing cannot be sustained
• Construction or fire-safety requirements are prohibitive
• The hospital cannot support emergencies or complications
• Financial viability depends on unsupported indications
• Patients would be better served through regional coordination

The appropriate growth strategy may be an additional chamber at an established center, a new outpatient service, a regional critical-care hub, or no new chamber at all.

Sustainable Growth Requires Clinical Discipline

The growth of hyperbaric programs in hospitals reflects genuine clinical needs. Diabetes-related limb complications remain substantial, cancer survivors require management of delayed treatment effects, and complex trauma and reconstruction create time-sensitive tissue-salvage problems. (CDC)

Hospital infrastructure can make HBOT safer and more coordinated by connecting the chamber with surgery, vascular care, infectious disease, oncology, emergency medicine, and critical care.

That same infrastructure also creates an obligation. Programs must resist the pressure to fill chambers with marginal indications, fixed treatment courses, or patients whose principal barriers have not been addressed.

The strongest growth model is not the one that produces the most treatments. It is the one that identifies appropriate patients, integrates HBOT with definitive care, measures meaningful outcomes, protects safety, and remains financially sustainable without depending on overutilization.

How Advances in Digital Controls, Environmental Monitoring, Critical-Care Equipment, Fire Safety, and Maintenance Are Changing HBOT Delivery

New hyperbaric chamber technology is not primarily about reaching higher pressures. Modern medical chambers already operate within pressure ranges adequate for established hyperbaric oxygen therapy and therapeutic recompression protocols. The more consequential advances involve how chamber systems control pressure, manage treatment gases, monitor patients, detect environmental changes, support critical care, and document maintenance.

Hyperbaric chambers remain Class II medical devices in the United States. The FDA clears these devices through the 510(k) process, and cleared systems can be identified through product code CBF. In August 2025, the agency reminded facilities that technological sophistication does not replace staff training, continuous patient supervision, grounding, fire prevention, maintenance, and strict control of items introduced into the chamber. (U.S. Food and Drug Administration)

The direction of chamber development is therefore best described as safer integration. Pressure-vessel engineering remains the foundation, but newer systems increasingly combine that structure with digital controls, environmental sensors, treatment-data capture, improved patient access, and equipment designed for more complex clinical care.

Pressure-Vessel Engineering Remains the Foundation

A hyperbaric chamber must safely contain one or more people while maintaining a controlled pressure differential. New software, monitors, and treatment features have limited value when the underlying vessel, windows, doors, penetrations, piping, or pressure-control systems are not engineered and maintained properly.

The current ASME PVHO-1 standard is the 2023 edition. It establishes requirements for the design, fabrication, inspection, testing, marking, and certification of pressure vessels for human occupancy and their associated piping systems. Medical hyperbaric chambers, recompression chambers, diving bells, and related pressure vessels fall within its scope. (ASME)

Post-construction safety is addressed separately. The 2025 edition of ASME PVHO-2 provides technical criteria for the operation and maintenance of vessels built under PVHO-1. It also addresses the continuing serviceability of acrylic windows under their specific environmental and operating conditions. (ASME)

These standards illustrate an important point about chamber technology: innovation must account for the entire equipment lifecycle. A chamber is exposed to thousands of compression and decompression cycles, repeated cleaning, environmental stress, oxygen service, mechanical wear, and changes in installed equipment. Long-term safety depends on inspection and maintenance as much as original design.

Hospitals should verify which editions of ASME, NFPA 99, building codes, and local regulations have been adopted by the authority having jurisdiction. The newest published standard is not necessarily the edition legally enforced in every location.

Digital Hyperbaric Chamber Control Systems

Older chamber systems relied more heavily on mechanical gauges, manual valves, and operator calculations. Modern chambers increasingly use human-machine interfaces, programmable controls, electronic pressure sensing, and visual treatment-profile displays.

An FDA-cleared multiplace chamber system provides an example of this architecture. Its touchscreen control console can initiate and monitor treatment, administer breathing gases, monitor oxygen, optionally monitor carbon dioxide, track relative humidity, regulate temperature, operate compartment doors and lighting, and support administrative functions. The system also incorporates manual backup controls for pressurization and depressurization if the automated feature becomes unavailable.

Potential advantages of digital controls include:

• More consistent compression and decompression rates
• Clear visualization of the prescribed treatment profile
• Timed oxygen periods and air breaks
• Integrated pressure and environmental alarms
• Reduced dependence on handwritten calculations
• More complete treatment records
• Easier identification of deviations from the prescription

Automation can reduce some forms of human error, but it introduces software, sensor, power, and interface failure modes. Manual control capability remains essential. Staff must understand how the chamber behaves. Staff must understand how the chamber behaves when a touchscreen freezes, a sensor becomes inaccurate, an automatic valve fails, or power is interrupted.

A digital chamber should not become an unattended chamber. The FDA continues to require appropriate patient monitoring and supervision throughout trea(U.S. Food and Drug Administration)he degree of automation. citeturn529094view0

Integrated Gas and Environmental Monitoring

Environmental monitoring is becoming a more important area of chamber development. Pressure alone does not describe the condition inside the vessel.

Depending on chamber type and operating method, the clinical team may need to monitor:

• Oxygen concentration
• Carbon dioxide concentration
• Temperature
• Relative humidity
• Ventilation or purge flow
• Breathing-gas pressure
• Gas-source identity
• Fire-suppression readiness

In a multiplace chamber, the vessel is commonly pressurized with air while patients receive oxygen through masks, hoods, or ventilator circuits. Oxygen leakage from these systems can increase the ambient chamber oxygen concentration, so ventilation and oxygen analysis are central fire-safety controls.

A monoplace chamber is commonly pressurized with oxygen, making environmental measurement important for different reasons. Oxygen is consumed, carbon dioxide is produced, heat and humidity may accumulate, and the sampling location may not perfectly represent the environment immediately surrounding the patient.

A 2024 study evaluated a mechanically improved gas-monitoring system for monoplace chambers. The investigators measured oxygen, carbon dioxide, humidity, and temperature at different pressures and found that sampling-system design could affect how accurately the monitor represented conditions inside the chamber. The project highlights the need to validate sensors, sampling lines, cooling systems, and gas-flow patterns under actual hyperbaric conditions rather than assuming that a surface-calibrated mo(PubMed Central (PMC))ure. citeturn577741search0turn577741search4

Future systems may incorporate redundant sensing, automated calibration reminders, rate-of-change alarms, and continuous trend displays. The meaningful advance will not simply be the addition of more numbers. It will be the ability to distinguish a true environmental hazard from sensor drift, sampling delay, condensation, or equipment malfunction.

Smarter Alarms and Treatment Verification

Traditional alarms may indicate high pressure, low gas supply, elevated oxygen concentration, loss of power, or another equipment abnormality. More advanced systems can compare multiple data streams and provide context-sensitive alerts.

A treatment-verification system could theoretically compare:

• The physician’s prescription
• The selected chamber profile
• Actual pressure over time
• Oxygen-breathing periods
• Air breaks
• Compression and decompression rates
• Environmental readings
• Interruptions or emergency events

This could help detect an incorrect protocol before treatment begins or identify a difference between the prescribed and delivered oxygen dose.

Digital verification should be designed carefully. Excessive or poorly prioritized alarms can produce alarm fatigue, while automated documentation can reproduce incorrect information throughout the medical record. Hyperbaric programs still need a deliberate pre-treatment safety pause in which qualified personnel verify the patient, diagnosis, chamber, pressure, gas, duration, air breaks, and emergency plan.

Fire-Prevention Technology

Fire remains one of the most consequential hazards in hyperbaric medicine. Elevated oxygen concentration does not independently ignite, but it makes combustible materials easier to ignite and allows fire to burn more rapidly and intensely.

Modern multiplace systems may incorporate fixed fire-deluge systems, hand lines, oxygen analyzers, ventilation controls, emergency gas shutoff, pressure-rated water storage, alarm systems, and centralized activation from the control console. An FDA 510(k) summary for a multiplace system describes both a primary deluge system and a system. citeturn740981view0turn529094view5

No fire-suppression system makes ignition acceptable. The primary strategy remains prevention through:

• Approved clothing and linens
• Control of static electricity
• Proper grounding
• Review of dressings and skin products
• Exclusion of prohibited electronics
• Equipment compatibility assessment
• Chamber cleaning
• Staff training
• Continuous patient observation

The FDA’s 2025 safety communication followed reports of serious injuries and deaths associated with HBOT devices. The agency specifically emphasized proper grounding, avoidance of prohibited electrical or static-producing items, compatible clothing, staff education, supe(U.S. Food and Drug Administration)rer-defined maintenance. citeturn529094view0

Future fire-safety systems may include more responsive oxygen sensors, automatic ventilation adjustment, equipment identification, electronic pre-treatment checklists, and improved detection of abnormal heat or electrical activity. These technologies should reinforce strict material control, not create permission to bring ordinary consumer electronics into an oxygen-enriched chamber.

Hyperbaric-Compatible Patient Monitoring

Clinical monitoring under pressure presents unique engineering challenges. Gas-filled components change volume, gas density increases, pressure can alter equipment calibration, and electrical devices may create ignition or compatibility concerns.

Stable outpatients may require relatively basic observation. Critically ill patients may require:

• Continuous electrocardiography
• Invasive blood-pressure monitoring
• Pulse oximetry
• Capnography
• Mechanical ventilation
• Infusion pumps
• Airway-pressure monitoring
• Temperature monitoring
• Suction
• Immediate access to emergency medication

International critical-care guidance states that monitoring and treatment should not be reduced merely because the patient is receiving HBOT. Chambers intended for intensive-care patients should be equipped to continue necessary organ support, and every device introduced into the chamber shou(PubMed)ed for hyperbaric use. citeturn974827search1

Equipment performance may change with pressure. Increased gas density can influence ventilator flow, airway resistance, delivered tidal volume, and carbon dioxide clearance. Some monitoring values require pressure-specific interpretation. Critical-care HBOT therefore depends on more than fitting equipment through the chamber door. It requires performance testing, fire-safety assessm(PubMed)ing. citeturn974827search3turn974827search6

New chamber technology is increasingly valuable when it allows the hospital to maintain ICU-level care instead of interrupting it.

Wireless Point-of-Care Imaging

Point-of-care ultrasound is emerging as a potentially useful tool inside multiplace chambers. It could allow clinicians to assess cardiac function, pulmonary findings, vascular access, free fluid, or other acute changes without decompressing solely to obtain bedside imaging.

A 2023 proof-of-concept study evaluated a wireless handheld ultrasound device in a multiplace hyperbaric environment. The device maintained image quality and wireless connectivity during testing, allowing it to communicate with a display outside the chamber. The investigators also identified a pressure-related issue involving the device’s power button, demonstrating why apparently suitable consumer-style electronics require formal hyperbaric e(PubMed)ion. citeturn281193search0turn281193search2

This work does not mean that any wireless ultrasound device can be carried into any chamber. Equipment must be evaluated for the exact chamber class, oxygen environment, pressure, battery system, enclosure, and intended clinical use.

The larger opportunity is significant. Safe wireless transmission could reduce the amount of powered equipment inside the chamber while allowing clinicians outside to view physiologic or imaging information in real time.

Chamber-Compatible Ventilation and Infusion Technology

Mechanical ventilation under pressure has historically required specialized equipment and substantial staff expertise. Modern portable ventilators, monitors, and infusion systems may offer better performance and familiar ICU-style interfaces, but they still require validation at the pressures where they will be used.

Published hyperbaric equipment studies have tested transport ventilators at several treatment pressures and have demonstrated that some systems can perform adequately after structured evaluation. This type of testing measures delivered volume, airway pressure, oxygen concentration, triggering, alarms, and device temperature rather than assum(UHMS)d. citeturn974827search16turn974827search17

The most useful advances will provide:

• Reliable ventilation across treatment pressures
• Pressure-corrected flow and volume measurement
• Appropriate disconnection and pressure alarms
• Safe oxygen and air-break delivery
• Better waveform monitoring
• Smaller equipment footprints
• External displays or controls when feasible
• Battery and electrical systems evaluated for chamber use

Not every advanced ICU technology is currently compatible with hyperbaric treatment. Reviews have identified significant limitations with highly complex systems such as extracorporeal membrane oxygenation a(PubMed)r circulatory support. citeturn974827search3

Hospitals should define their chamber’s actual critical-care capability rather than assuming that any patient can be treated because a stretcher fits inside.

Patient Access and Chamber Configuration

Contemporary chamber design is also addressing patient mobility, obesity, anxiety, and the need for direct care.

Acrylic monoplace chambers provide broad visual contact with staff outside the vessel. Newer configurations may offer greater internal diameter, powered patient-transfer systems, adjustable positioning, and improved communication. These features can make treatment more practical for patients with limited mobility or complex wounds.

Multiplace systems can be configured with multiple independently controlled compartments, allowing one section to remain at treatment pressure while another is used to transfer personnel or supplies. Rectangular chamber designs can provide a room-like interior, flexible seating or stretcher arrangements, and space for critical-care staff and equipment. FDA documentation for one rectangular multiplace family describes configurations with multiple compartments anections. citeturn740981view0turn529094view5

The choice between cylindrical, rectangular, monoplace, and multiplace systems should be based on clinical scope rather than appearance. A wider chamber may improve patient comfort but require greater construction, staffing, gas, fire-protection, and maintenance resources.

Temperature, Humidity, and Patient Comfort

Temperature and humidity are clinical and operational variables, not simply comfort features. Compression can increase chamber temperature, while decompression can cause cooling. Patients may remain inside for several hours, and critically ill patients may have limited ability to regulate body temperature.

Environmental-control systems can manage heating, cooling, humidity, and airflow. Integrated monitoring allows operators to observe trends and adjust the chamber environment before discomfort or condensation becomes significant. FDA-cleared multiplace technology has incorporated temperature and relative-humidity ntral control interface. citeturn141888view0

Improved communication, lighting, visual access, noise reduction, and external entertainment displays may also help patients tolerate long treatment courses. These features can reduce anxiety and treatment interruption, but they must be engineered without introducing unapproved electrical devices into the chamber.

Digital Documentation and Electronic Medical Records

Hyperbaric treatment produces a large amount of technical information:

• Chamber and patient identification
• Pressure profile
• Compression and decompression rates
• Oxygen periods
• Air breaks
• Environmental readings
• Vital signs
• Glucose measurements
• Treatment interruptions
• Adverse events
• Operator actions

Digital systems can transfer some of this information directly into treatment records, reducing transcription and making it easier to review a delivered treatment profile.

The greatest value may be in connecting chamber data with clinical outcomes. A program could compare oxygen dose and treatment completion with wound healing, radiation-injury symptoms, graft survival, adverse events, or other indication-specific measures.

Direct data transfer should not eliminate clinical narrative. A pressure graph cannot explain why treatment was interrupted, why the physician modified the protocol, or whether the patient developed a new symptom.

Cybersecurity and change control also become relevant when chamber controls and medical records are networked. Hospitals need to determine who can modify treatment profiles, how software updates are validated, whether remote access is permitted, and how a safe manual mode is preserved during a digital outage.

Predictive Maintenance and Chamber Lifecycle Management

Hyperbaric facilities have traditionally relied on scheduled preventive maintenance, cycle counts, inspection records, and manufacturer service intervals. Newer sensor and data systems create the possibility of more predictive maintenance.

A system may eventually detect trends involving:

• Valve response time
• Compressor performance
• Pressure stability
• Gas consumption
• Seal leakage
• Temperature changes
• Analyzer drift
• Door operation
• Alarm frequency

Predictive analytics could identify deterioration before it causes chamber downtime or creates a safety event. This approach should supplement the formal inspection and maintenance requirements established by the manufacturer, ASME standards, NFPA requirements, and the authority having jurisdiction.

The 2025 ASME PVHO-2 standard’s focus on post-construction operation, maintenance, and acrylic-window serviceability reinforces the importance of managing the complete chamber lifecycle rather than treating insta(ASME)the engineering process. citeturn529094view2

Transportable and Remote Recompression Systems

Portable and transportable pressure systems are being developed for military, maritime, remote diving, and disaster settings where access to a fixed recompression facility may require many hours.

Some systems are intended to provide initial recompression or transport under pressure before transfer into a larger treatment chamber. Divers Alert Network has described transportable systems designed to support injured divers in remote environments and, in selected (Divers Alert Network)nsfer under pressure. citeturn974827search31

These systems do not create a complete hospital hyperbaric program. Their safe use requires trained personnel, breathing-gas supplies, communications, monitoring, validated treatment or transfer protocols, and an identified receiving facility.

A portable chamber marketed for home or wellness use should not be confused with a medical recompression system capable of treating decompression sickness or an unstable patient.

FDA Clearance Does Not Prove Clinical Superiority

A chamber may incorporate a touchscreen, additional sensors, a wider interior, or a new control architecture and still use the same fundamental therapeutic principles as an older system.

The FDA 510(k) pathway requires a manufacturer to demonstrate that a device is substantially equivalent to a legally marketed predicate device. The comparison may include intended use, design, energy delivery, materials, performance, safety, effec(U.S. Food and Drug Administration)ics. citeturn194639search0turn194639search4

Clearance establishes that the device can be marketed for its cleared use. It does not automatically establish that it produces better clinical outcomes than other cleared chambers.

Hospitals evaluating new technology should ask:

• Is the exact system FDA cleared under product code CBF?
• What is its cleared intended use?
• Which pressure-vessel and fire codes does it meet?
• What manual backup systems are provided?
• Which monitors and accessories have been tested under pressure?
• How are software changes validated?
• What maintenance and window-replacement requirements apply?
• Can the manufacturer provide long-term parts and service support?
• Does the technology improve safety, clinical capability, or workflow in a measurable way?

Marketing language such as smart, advanced, medical grade, or next generation should not replace regulatory and engineering documentation.

Soft Chambers and Medical Hyperbaric Systems Are Not Equivalent

Flexible or low-pressure chambers are frequently marketed for wellness, recovery, athletic performance, and a broad range of unestablished uses. Their pressure, oxygen delivery, construction, fire protection, monitoring, and emergency capabilities can differ substantially from hospital hyperbaric systems.

The FDA advises facilities to confirm that an HBOT device is cleared and notes that cleared chambers can be identified through product code CBF. It also emphasizes following the instructions for the specific device, because safe operating requirements (U.S. Food and Drug Administration)e across chamber models. citeturn529094view0

A system should not be described as equivalent to hospital HBOT merely because it encloses a person and creates pressure. The delivered oxygen dose, pressure-vessel design, gas environment, supervision, and intended use all matter.

Technology Should Reduce Risk, Not Reduce Staffing

One of the most important limits of automation is the temptation to use it as a substitute for qualified personnel.

A chamber may automatically control pressure, time air breaks, record environmental measurements, and display patient video. It cannot independently perform a neurologic examination, interpret chest pain, recognize subtle confusion, protect a patient during a seizure, or determine whether urgent decompression creates more risk than remaining at pressure.

The FDA continues to emphasize trained staff and(U.S. Food and Drug Administration)or the entire treatment. citeturn529094view0

New technology should allow the hyperbaric team to detect problems earlier and respond more effectively. It should not justify unsafe patient-to-staff ratios, remote unattended operation, or reliance on one operator to manage more chambers than can be continuously observed.

Evaluating New Hyperbaric Chamber Technology

A hospital or clinical program should assess new technology across several domains.

Clinical capability: Determine whether the chamber can safely treat the intended outpatient, emergency, pediatric, bariatric, ventilated, or critically ill population.

Engineering compliance: Verify pressure-vessel certification, fire-code compliance, medical gas requirements, electrical systems, environmental controls, structural requirements, and adopted local codes. ASME PVHO-1, ASME PVHO-2, and NFPA 99 r(ASME)n529094view1turn529094view2turn901302search8

Safety architecture: Review grounding, fire suppression, gas monitoring, emergency ventilation, backup controls, alarm behavior, prohibited-item management, and failure modes.

Equipment compatibility: Identify which ventilators, monitors, pumps, dressings, stretchers, and accessories have been tested for the exact chamber and pressure range.

Human factors: Observe whether controls are intuitive, alarms are prioritized, manual override is accessible, and staff can maintain visual and verbal contact with patients.

Data management: Determine how treatment profiles are stored, exported, secured, audited, and reconciled with the medical record.

Lifecycle support: Evaluate preventive maintenance, replacement parts, window inspections, service response, software support, staff education, and expected downtime.

The most advanced chamber is not necessarily the one with the largest touchscreen or highest advertised pressure. It is the system that allows a qualified clinical team to deliver the prescribed oxygen dose reliably, recognize deterioration quickly, manage emergencies safely, and maintain the equipment throughout its service life.

Future chamber development will likely bring better sensing, more complete treatment-data integration, improved critical-care devices, wireless monitoring, and earlier detection of equipment deterioration. Those advances are valuable when they strengthen the fundamentals of hyperbaric medicine: a sound pressure vessel, disciplined fire prevention, qualified personnel, continuous observation, and treatment tied to a defensible clinical indication.